US20080026083A1 - Antimicrobial and pesticidal compositions and methods comprising reduced monoterpene oil extracted from myrtaceae - Google Patents
Antimicrobial and pesticidal compositions and methods comprising reduced monoterpene oil extracted from myrtaceae Download PDFInfo
- Publication number
- US20080026083A1 US20080026083A1 US11/779,146 US77914607A US2008026083A1 US 20080026083 A1 US20080026083 A1 US 20080026083A1 US 77914607 A US77914607 A US 77914607A US 2008026083 A1 US2008026083 A1 US 2008026083A1
- Authority
- US
- United States
- Prior art keywords
- virus
- oil
- eucalyptus
- infection
- base composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 132
- 238000000034 method Methods 0.000 title claims abstract description 44
- 229930003658 monoterpene Natural products 0.000 title claims abstract description 23
- 150000002773 monoterpene derivatives Chemical class 0.000 title claims abstract description 23
- 235000002577 monoterpenes Nutrition 0.000 title claims abstract description 23
- 241000219926 Myrtaceae Species 0.000 title claims abstract description 13
- 230000002829 reductive effect Effects 0.000 title claims description 4
- 230000000845 anti-microbial effect Effects 0.000 title description 10
- 230000000361 pesticidal effect Effects 0.000 title description 4
- 208000015181 infectious disease Diseases 0.000 claims abstract description 71
- 241001465754 Metazoa Species 0.000 claims abstract description 54
- 238000011282 treatment Methods 0.000 claims abstract description 38
- 239000003921 oil Substances 0.000 claims abstract description 29
- 239000000341 volatile oil Substances 0.000 claims abstract description 28
- 230000000813 microbial effect Effects 0.000 claims abstract description 9
- 238000011321 prophylaxis Methods 0.000 claims abstract description 7
- 230000002538 fungal effect Effects 0.000 claims abstract description 4
- 241000256844 Apis mellifera Species 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 10
- 206010061217 Infestation Diseases 0.000 claims description 9
- 229930004725 sesquiterpene Natural products 0.000 claims description 7
- 150000004354 sesquiterpene derivatives Chemical class 0.000 claims description 7
- 208000026681 Paratuberculosis Diseases 0.000 claims description 5
- 241000282849 Ruminantia Species 0.000 claims description 5
- 241000607479 Yersinia pestis Species 0.000 claims description 5
- 201000002266 mite infestation Diseases 0.000 claims description 5
- 241000700605 Viruses Species 0.000 description 48
- 241000271566 Aves Species 0.000 description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
- 241000378544 Melaleuca quinquenervia Species 0.000 description 28
- 201000010099 disease Diseases 0.000 description 28
- 238000012360 testing method Methods 0.000 description 28
- 241000257303 Hymenoptera Species 0.000 description 26
- 235000019198 oils Nutrition 0.000 description 24
- 239000000243 solution Substances 0.000 description 19
- 241000238876 Acari Species 0.000 description 16
- 241000251468 Actinopterygii Species 0.000 description 15
- 235000019688 fish Nutrition 0.000 description 15
- 241000894007 species Species 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 241000238631 Hexapoda Species 0.000 description 14
- 230000012010 growth Effects 0.000 description 14
- 241000589875 Campylobacter jejuni Species 0.000 description 13
- 241000186779 Listeria monocytogenes Species 0.000 description 13
- 230000037396 body weight Effects 0.000 description 13
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 12
- 241000283690 Bos taurus Species 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 235000013601 eggs Nutrition 0.000 description 11
- 235000013305 food Nutrition 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 244000045947 parasite Species 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 241000287828 Gallus gallus Species 0.000 description 8
- 241000607142 Salmonella Species 0.000 description 8
- 241000193996 Streptococcus pyogenes Species 0.000 description 8
- 108010059993 Vancomycin Proteins 0.000 description 8
- 235000013330 chicken meat Nutrition 0.000 description 8
- 230000034994 death Effects 0.000 description 8
- 231100000517 death Toxicity 0.000 description 8
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 8
- 229960003165 vancomycin Drugs 0.000 description 8
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 8
- 208000035143 Bacterial infection Diseases 0.000 description 7
- 241000194032 Enterococcus faecalis Species 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 208000022362 bacterial infectious disease Diseases 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 150000003505 terpenes Chemical class 0.000 description 7
- 235000007586 terpenes Nutrition 0.000 description 7
- WRYLYDPHFGVWKC-UHFFFAOYSA-N 4-terpineol Chemical compound CC(C)C1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 241000187482 Mycobacterium avium subsp. paratuberculosis Species 0.000 description 6
- 240000008474 Pimenta dioica Species 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 229930003427 Vitamin E Natural products 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229940046009 vitamin E Drugs 0.000 description 6
- 235000019165 vitamin E Nutrition 0.000 description 6
- 239000011709 vitamin E Substances 0.000 description 6
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 5
- WRYLYDPHFGVWKC-SNVBAGLBSA-N 4-Terpineol Natural products CC(C)[C@]1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-SNVBAGLBSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 241000194033 Enterococcus Species 0.000 description 5
- 241000194031 Enterococcus faecium Species 0.000 description 5
- 244000166124 Eucalyptus globulus Species 0.000 description 5
- CKZXONNJVHXSQM-UHFFFAOYSA-N Ledol Natural products CC(C)C1CCC(C)(O)C2C3CC(C)CC123 CKZXONNJVHXSQM-UHFFFAOYSA-N 0.000 description 5
- 240000005125 Myrtus communis Species 0.000 description 5
- 241000191963 Staphylococcus epidermidis Species 0.000 description 5
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 5
- 241000895647 Varroa Species 0.000 description 5
- -1 aminoglycosides Chemical class 0.000 description 5
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 5
- 244000078703 ectoparasite Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000002480 mineral oil Substances 0.000 description 5
- 235000010446 mineral oil Nutrition 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 231100000161 signs of toxicity Toxicity 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- ITYNGVSTWVVPIC-DHGKCCLASA-N (-)-allo-Aromadendrene Chemical compound C([C@@H]1[C@H]2C1(C)C)CC(=C)[C@@H]1[C@H]2[C@H](C)CC1 ITYNGVSTWVVPIC-DHGKCCLASA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 241000700198 Cavia Species 0.000 description 4
- 241000193468 Clostridium perfringens Species 0.000 description 4
- 244000165963 Eucalyptus camaldulensis Species 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 4
- 244000185238 Lophostemon confertus Species 0.000 description 4
- 241000366182 Melaleuca alternifolia Species 0.000 description 4
- 241001264681 Melaleuca linariifolia Species 0.000 description 4
- 241000257226 Muscidae Species 0.000 description 4
- 241000186367 Mycobacterium avium Species 0.000 description 4
- 241000187480 Mycobacterium smegmatis Species 0.000 description 4
- 235000013418 Myrtus communis Nutrition 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- 241001674048 Phthiraptera Species 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- 241000725681 Swine influenza virus Species 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 238000002814 agar dilution Methods 0.000 description 4
- 230000002421 anti-septic effect Effects 0.000 description 4
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000009036 growth inhibition Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 241000712461 unidentified influenza virus Species 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- GRWFGVWFFZKLTI-UHFFFAOYSA-N α-pinene Chemical compound CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 4
- YHQGMYUVUMAZJR-UHFFFAOYSA-N α-terpinene Chemical compound CC(C)C1=CC=C(C)CC1 YHQGMYUVUMAZJR-UHFFFAOYSA-N 0.000 description 4
- YKFLAYDHMOASIY-UHFFFAOYSA-N γ-terpinene Chemical compound CC(C)C1=CCC(C)=CC1 YKFLAYDHMOASIY-UHFFFAOYSA-N 0.000 description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 3
- AYXPYQRXGNDJFU-QTPLKFIXSA-N (-)-Globulol Chemical compound [C@H]1([C@](CC[C@@H]2[C@H]3C2(C)C)(C)O)[C@H]3[C@H](C)CC1 AYXPYQRXGNDJFU-QTPLKFIXSA-N 0.000 description 3
- AYXPYQRXGNDJFU-QUMMREBQSA-N (-)-Globulol Natural products O[C@@]1(C)[C@H]2[C@H]([C@H](C)CC2)[C@@H]2C(C)(C)[C@@H]2CC1 AYXPYQRXGNDJFU-QUMMREBQSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 3
- 241000711404 Avian avulavirus 1 Species 0.000 description 3
- 241001264766 Callistemon Species 0.000 description 3
- 241000010789 Callistemon lanceolatus Species 0.000 description 3
- 241001264734 Callistemon viminalis Species 0.000 description 3
- 241000193403 Clostridium Species 0.000 description 3
- 241001126268 Cooperia Species 0.000 description 3
- 241000238424 Crustacea Species 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 235000004722 Eucalyptus citriodora Nutrition 0.000 description 3
- 244000187656 Eucalyptus cornuta Species 0.000 description 3
- 244000004281 Eucalyptus maculata Species 0.000 description 3
- 241001074710 Eucalyptus populnea Species 0.000 description 3
- 244000233576 Feijoa sellowiana Species 0.000 description 3
- 235000012068 Feijoa sellowiana Nutrition 0.000 description 3
- 241000606768 Haemophilus influenzae Species 0.000 description 3
- 208000006968 Helminthiasis Diseases 0.000 description 3
- 208000002979 Influenza in Birds Diseases 0.000 description 3
- 241000589248 Legionella Species 0.000 description 3
- 208000007764 Legionnaires' Disease Diseases 0.000 description 3
- 240000003553 Leptospermum scoparium Species 0.000 description 3
- 241001490312 Lithops pseudotruncatella Species 0.000 description 3
- 241000588655 Moraxella catarrhalis Species 0.000 description 3
- 238000011887 Necropsy Methods 0.000 description 3
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 3
- 241000243795 Ostertagia Species 0.000 description 3
- 241000606856 Pasteurella multocida Species 0.000 description 3
- 235000006990 Pimenta dioica Nutrition 0.000 description 3
- 240000006463 Pimenta racemosa Species 0.000 description 3
- 244000169711 Psidium cattleianum Species 0.000 description 3
- 241000193985 Streptococcus agalactiae Species 0.000 description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 description 3
- 241001312524 Streptococcus viridans Species 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000000642 acaricide Substances 0.000 description 3
- UIDUJXXQMGYOIN-UHFFFAOYSA-N aromadendrin Natural products CC1(C)C2C1CCC(C)C1C2C(C)CC1 UIDUJXXQMGYOIN-UHFFFAOYSA-N 0.000 description 3
- 206010064097 avian influenza Diseases 0.000 description 3
- 244000144987 brood Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- RBNWAMSGVWEHFP-UHFFFAOYSA-N cis-p-Menthan-1,8-diol Natural products CC(C)(O)C1CCC(C)(O)CC1 RBNWAMSGVWEHFP-UHFFFAOYSA-N 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 244000079386 endoparasite Species 0.000 description 3
- 229940032049 enterococcus faecalis Drugs 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- NKIWRYQBASKLRK-UHFFFAOYSA-N globulol Natural products CC1CCC2CC(C)(O)CC3C(C12)C3(C)C NKIWRYQBASKLRK-UHFFFAOYSA-N 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 244000000013 helminth Species 0.000 description 3
- 239000012678 infectious agent Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 235000001510 limonene Nutrition 0.000 description 3
- 229940087305 limonene Drugs 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 3
- 230000003071 parasitic effect Effects 0.000 description 3
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 239000010677 tea tree oil Substances 0.000 description 3
- 229940111630 tea tree oil Drugs 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- FUCYIEXQVQJBKY-ZFWWWQNUSA-N (+)-δ-Cadinene Chemical compound C1CC(C)=C[C@H]2[C@H](C(C)C)CCC(C)=C21 FUCYIEXQVQJBKY-ZFWWWQNUSA-N 0.000 description 2
- WRYLYDPHFGVWKC-JTQLQIEISA-N (R)-(-)-p-Menth-1-en-4-ol Natural products CC(C)[C@@]1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-JTQLQIEISA-N 0.000 description 2
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 2
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 2
- 241000193792 Aerococcus viridans Species 0.000 description 2
- 241000006099 Angophora costata Species 0.000 description 2
- 241000238421 Arthropoda Species 0.000 description 2
- 241000244186 Ascaris Species 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- 241001225321 Aspergillus fumigatus Species 0.000 description 2
- 206010063659 Aversion Diseases 0.000 description 2
- 241001148536 Bacteroides sp. Species 0.000 description 2
- 241000931178 Bunostomum Species 0.000 description 2
- 241000257161 Calliphoridae Species 0.000 description 2
- 241001264746 Callistemon rigidus Species 0.000 description 2
- 241001264730 Callistemon salignus Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 240000001817 Cereus hexagonus Species 0.000 description 2
- 241000662776 Chamelaucium uncinatum Species 0.000 description 2
- 241000606153 Chlamydia trachomatis Species 0.000 description 2
- 241000222290 Cladosporium Species 0.000 description 2
- 241000710777 Classical swine fever virus Species 0.000 description 2
- 241001480081 Corymbia ficifolia Species 0.000 description 2
- 241001399644 Corymbia torelliana Species 0.000 description 2
- BZKFMUIJRXWWQK-UHFFFAOYSA-N Cyclopentenone Chemical compound O=C1CCC=C1 BZKFMUIJRXWWQK-UHFFFAOYSA-N 0.000 description 2
- 206010011906 Death Diseases 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 240000002506 Eucalyptus caesia Species 0.000 description 2
- 240000008106 Eucalyptus cinerea Species 0.000 description 2
- 244000165852 Eucalyptus citriodora Species 0.000 description 2
- 241001528275 Eucalyptus deglupta Species 0.000 description 2
- 244000091434 Eucalyptus erythronema Species 0.000 description 2
- 235000004692 Eucalyptus globulus Nutrition 0.000 description 2
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 2
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 2
- 241001493731 Eucalyptus macrocarpa Species 0.000 description 2
- 235000010705 Eucalyptus maculata Nutrition 0.000 description 2
- 244000088038 Eucalyptus mannifera Species 0.000 description 2
- 240000001602 Eucalyptus microtheca Species 0.000 description 2
- 240000003845 Eucalyptus nicholii Species 0.000 description 2
- 244000165918 Eucalyptus papuana Species 0.000 description 2
- 235000004695 Eucalyptus papuana Nutrition 0.000 description 2
- 241000006116 Eucalyptus pauciflora Species 0.000 description 2
- 241001074705 Eucalyptus perriniana Species 0.000 description 2
- 244000180111 Eucalyptus platypus Species 0.000 description 2
- 241001480095 Eucalyptus preissiana Species 0.000 description 2
- 235000005219 Eucalyptus pulverulenta Nutrition 0.000 description 2
- 244000239659 Eucalyptus pulverulenta Species 0.000 description 2
- 240000006361 Eucalyptus saligna Species 0.000 description 2
- 235000005231 Eucalyptus sideroxylon Nutrition 0.000 description 2
- 240000007002 Eucalyptus tereticornis Species 0.000 description 2
- 244000158376 Eucalyptus tetraptera Species 0.000 description 2
- 244000273351 Eugenia aggregata Species 0.000 description 2
- 235000014035 Eugenia aggregata Nutrition 0.000 description 2
- 235000005245 Eugenia brasiliensis Nutrition 0.000 description 2
- 240000004607 Eugenia brasiliensis Species 0.000 description 2
- 244000061408 Eugenia caryophyllata Species 0.000 description 2
- 244000183945 Eugenia luschnathiana Species 0.000 description 2
- 235000003380 Eugenia luschnathiana Nutrition 0.000 description 2
- 235000009463 Eugenia smithii Nutrition 0.000 description 2
- 235000013420 Eugenia uniflora Nutrition 0.000 description 2
- 240000003813 Eugenia uniflora Species 0.000 description 2
- 241000701087 Felid alphaherpesvirus 1 Species 0.000 description 2
- 241000223218 Fusarium Species 0.000 description 2
- 241000701063 Gallid alphaherpesvirus 1 Species 0.000 description 2
- 241000243976 Haemonchus Species 0.000 description 2
- 241000711450 Infectious bronchitis virus Species 0.000 description 2
- 241000588915 Klebsiella aerogenes Species 0.000 description 2
- 244000011376 Leptospermum laevigatum Species 0.000 description 2
- 235000016887 Leptospermum scoparium Nutrition 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- WSTYNZDAOAEEKG-UHFFFAOYSA-N Mayol Natural products CC1=C(O)C(=O)C=C2C(CCC3(C4CC(C(CC4(CCC33C)C)=O)C)C)(C)C3=CC=C21 WSTYNZDAOAEEKG-UHFFFAOYSA-N 0.000 description 2
- 241001264691 Melaleuca ericifolia Species 0.000 description 2
- 241000378504 Melaleuca nesophila Species 0.000 description 2
- 241001502481 Meleagrid alphaherpesvirus 1 Species 0.000 description 2
- 241001468188 Melissococcus plutonius Species 0.000 description 2
- 241000895503 Metrosideros Species 0.000 description 2
- 241000895504 Metrosideros excelsa Species 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 2
- 244000170059 Myrciaria cauliflora Species 0.000 description 2
- 235000006992 Myrciaria cauliflora Nutrition 0.000 description 2
- 244000234179 Myrtus ugni Species 0.000 description 2
- 235000012093 Myrtus ugni Nutrition 0.000 description 2
- 241000244206 Nematoda Species 0.000 description 2
- 241001137882 Nematodirus Species 0.000 description 2
- 241001126829 Nosema Species 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- 241000193418 Paenibacillus larvae Species 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 241001123663 Penicillium expansum Species 0.000 description 2
- 241000191992 Peptostreptococcus Species 0.000 description 2
- 241000811796 Pseudopithomyces chartarum Species 0.000 description 2
- 235000012087 Psidium araca Nutrition 0.000 description 2
- 235000006978 Psidium cattleianum Nutrition 0.000 description 2
- 240000005633 Psidium guineense Species 0.000 description 2
- 244000236580 Psidium pyriferum Species 0.000 description 2
- 235000013929 Psidium pyriferum Nutrition 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 241000258242 Siphonaptera Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010062255 Soft tissue infection Diseases 0.000 description 2
- 206010041925 Staphylococcal infections Diseases 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 244000057717 Streptococcus lactis Species 0.000 description 2
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 2
- 244000223646 Syzygium francisii Species 0.000 description 2
- 244000234181 Syzygium samarangense Species 0.000 description 2
- 241001534765 Syzygium smithii Species 0.000 description 2
- 108010053950 Teicoplanin Proteins 0.000 description 2
- MOYAFQVGZZPNRA-UHFFFAOYSA-N Terpinolene Chemical compound CC(C)=C1CCC(C)=CC1 MOYAFQVGZZPNRA-UHFFFAOYSA-N 0.000 description 2
- 241000243797 Trichostrongylus Species 0.000 description 2
- 241001514640 Tristaniopsis laurina Species 0.000 description 2
- 206010047400 Vibrio infections Diseases 0.000 description 2
- TUWWTQRJWLLWJE-UHFFFAOYSA-N Viridiflorol Natural products CC1CCC2C1C3C(CCC2(O)O)C3(C)C TUWWTQRJWLLWJE-UHFFFAOYSA-N 0.000 description 2
- 208000021017 Weight Gain Diseases 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 231100000460 acute oral toxicity Toxicity 0.000 description 2
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 2
- QMAYBMKBYCGXDH-UHFFFAOYSA-N alpha-amorphene Natural products C1CC(C)=CC2C(C(C)C)CC=C(C)C21 QMAYBMKBYCGXDH-UHFFFAOYSA-N 0.000 description 2
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 2
- 229940088601 alpha-terpineol Drugs 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000003096 antiparasitic agent Substances 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 238000009360 aquaculture Methods 0.000 description 2
- 244000144974 aquaculture Species 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940038705 chlamydia trachomatis Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- YOCDGWMCBBMMGJ-UHFFFAOYSA-N delta-cadinene Natural products C1C=C(C)CC2C(C(C)C)CCC(=C)C21 YOCDGWMCBBMMGJ-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 206010014665 endocarditis Diseases 0.000 description 2
- WGTRJVCFDUCKCM-UHFFFAOYSA-N ent-ledene Natural products C1CC2C(C)(C)C2C2C(C)CCC2=C1C WGTRJVCFDUCKCM-UHFFFAOYSA-N 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 208000005562 infectious bovine rhinotracheitis Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 235000009733 malagueta Nutrition 0.000 description 2
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 235000003569 mottlecah Nutrition 0.000 description 2
- 229940013390 mycoplasma pneumoniae Drugs 0.000 description 2
- 230000002956 necrotizing effect Effects 0.000 description 2
- 231100000706 no observed effect level Toxicity 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- NDVASEGYNIMXJL-UHFFFAOYSA-N sabinene Chemical compound C=C1CCC2(C(C)C)C1C2 NDVASEGYNIMXJL-UHFFFAOYSA-N 0.000 description 2
- USDOQCCMRDNVAH-UHFFFAOYSA-N sigma-cadinene Natural products C1C=C(C)CC2C(C(C)C)CC=C(C)C21 USDOQCCMRDNVAH-UHFFFAOYSA-N 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000001256 steam distillation Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 244000239645 swamp mahogany Species 0.000 description 2
- 235000005221 swamp mahogany Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960001608 teicoplanin Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 101150037181 vanB gene Proteins 0.000 description 2
- AYXPYQRXGNDJFU-IMNVLQEYSA-N viridiflorol Chemical compound [C@@H]1([C@@](CC[C@@H]2[C@H]3C2(C)C)(C)O)[C@H]3[C@H](C)CC1 AYXPYQRXGNDJFU-IMNVLQEYSA-N 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 244000088012 yorrell Species 0.000 description 2
- 235000002644 yorrell Nutrition 0.000 description 2
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 2
- 150000003952 β-lactams Chemical class 0.000 description 2
- NDVASEGYNIMXJL-NXEZZACHSA-N (+)-sabinene Natural products C=C1CC[C@@]2(C(C)C)[C@@H]1C2 NDVASEGYNIMXJL-NXEZZACHSA-N 0.000 description 1
- XTJLXXCARCJVPJ-TWTPFVCWSA-N (2e,4e)-hepta-2,4-diene Chemical compound CC\C=C\C=C\C XTJLXXCARCJVPJ-TWTPFVCWSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- QHDHNVFIKWGRJR-UHFFFAOYSA-N 1-cyclohexenol Chemical compound OC1=CCCCC1 QHDHNVFIKWGRJR-UHFFFAOYSA-N 0.000 description 1
- ZITVKGIRQCDOSX-UHFFFAOYSA-N 1h-cyclopropa[a]naphthalene Chemical compound C1=CC=CC2=C3CC3=CC=C21 ZITVKGIRQCDOSX-UHFFFAOYSA-N 0.000 description 1
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 description 1
- 241001580838 Acarapis woodi Species 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 241000607528 Aeromonas hydrophila Species 0.000 description 1
- 241001514646 Agonis flexuosa Species 0.000 description 1
- 241000588986 Alcaligenes Species 0.000 description 1
- 241000122170 Aliivibrio salmonicida Species 0.000 description 1
- ITYNGVSTWVVPIC-XGFWRYKXSA-N Alloaromadendrene Natural products C([C@@H]1[C@H]2C1(C)C)CC(=C)[C@@H]1[C@@H]2[C@H](C)CC1 ITYNGVSTWVVPIC-XGFWRYKXSA-N 0.000 description 1
- 241000223600 Alternaria Species 0.000 description 1
- 241001147657 Ancylostoma Species 0.000 description 1
- 241001465677 Ancylostomatoidea Species 0.000 description 1
- 241000256837 Apidae Species 0.000 description 1
- 241000256836 Apis Species 0.000 description 1
- 241000204727 Ascaridia Species 0.000 description 1
- 235000004379 Astartea fascicularis Nutrition 0.000 description 1
- 240000000850 Astartea fascicularis Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241001516406 Avian orthoreovirus Species 0.000 description 1
- 241000713842 Avian sarcoma virus Species 0.000 description 1
- 241000700663 Avipoxvirus Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 235000001351 Baeckea virgata Nutrition 0.000 description 1
- 244000026266 Baeckea virgata Species 0.000 description 1
- 241000606660 Bartonella Species 0.000 description 1
- 241001518086 Bartonella henselae Species 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000180135 Borrelia recurrentis Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241001148534 Brachyspira Species 0.000 description 1
- 241001265128 Callistemon linearis Species 0.000 description 1
- 241000948066 Calothamnus quadrifidus Species 0.000 description 1
- 241001523266 Calytrix tetragona Species 0.000 description 1
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Camphene hydrate Chemical compound C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 1
- 241000680578 Canid alphaherpesvirus 1 Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000007821 Cattley guava Nutrition 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 241000893172 Chabertia Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- 241000224483 Coccidia Species 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000031973 Conjunctivitis infective Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- VLXDPFLIRFYIME-GZBLMMOJSA-N Copaene Natural products C1C=C(C)[C@H]2[C@]3(C)CC[C@H](C(C)C)[C@H]2[C@@H]31 VLXDPFLIRFYIME-GZBLMMOJSA-N 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000006101 Corymbia maculata Species 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241001518260 Corynebacterium minutissimum Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000605721 Dichelobacter nodosus Species 0.000 description 1
- 241001147667 Dictyocaulus Species 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 241000464908 Elliptica Species 0.000 description 1
- 208000009701 Embryo Loss Diseases 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000520130 Enterococcus durans Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000230501 Equine herpesvirus sp. Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 241001074639 Eucalyptus albens Species 0.000 description 1
- 235000002583 Eucalyptus caesia Nutrition 0.000 description 1
- 241001501982 Eucalyptus campaspe Species 0.000 description 1
- 235000001912 Eucalyptus cinerea Nutrition 0.000 description 1
- 240000004181 Eucalyptus cladocalyx Species 0.000 description 1
- 241001493008 Eucalyptus conferruminata Species 0.000 description 1
- 235000002613 Eucalyptus eremophila Nutrition 0.000 description 1
- 240000008038 Eucalyptus eremophila Species 0.000 description 1
- 241001480110 Eucalyptus erythrocorys Species 0.000 description 1
- 235000002616 Eucalyptus erythronema Nutrition 0.000 description 1
- 235000000248 Eucalyptus formanii Nutrition 0.000 description 1
- 240000007031 Eucalyptus formanii Species 0.000 description 1
- 241001493510 Eucalyptus grossa Species 0.000 description 1
- 235000004504 Eucalyptus gunnii Nutrition 0.000 description 1
- 244000059939 Eucalyptus gunnii Species 0.000 description 1
- 235000002656 Eucalyptus incrassata Nutrition 0.000 description 1
- 244000086397 Eucalyptus incrassata Species 0.000 description 1
- 241001493696 Eucalyptus kruseana Species 0.000 description 1
- 241001493656 Eucalyptus largiflorens Species 0.000 description 1
- 241000172028 Eucalyptus lehmannii Species 0.000 description 1
- 235000000234 Eucalyptus mannifera Nutrition 0.000 description 1
- 235000001979 Eucalyptus megacornuta Nutrition 0.000 description 1
- 240000003648 Eucalyptus megacornuta Species 0.000 description 1
- 241001074673 Eucalyptus melliodora Species 0.000 description 1
- 235000003543 Eucalyptus nicholii Nutrition 0.000 description 1
- 241000109846 Eucalyptus orbifolia Species 0.000 description 1
- 235000003538 Eucalyptus platypus Nutrition 0.000 description 1
- 241001074707 Eucalyptus polyanthemos Species 0.000 description 1
- 241001494101 Eucalyptus pyriformis Species 0.000 description 1
- 241001495051 Eucalyptus rhodantha Species 0.000 description 1
- 241000400623 Eucalyptus rudis Species 0.000 description 1
- 240000009189 Eucalyptus sargentii Species 0.000 description 1
- 235000009687 Eucalyptus sargentii Nutrition 0.000 description 1
- 241000006125 Eucalyptus spathulata Species 0.000 description 1
- 235000003512 Eucalyptus stellulata Nutrition 0.000 description 1
- 240000000066 Eucalyptus stellulata Species 0.000 description 1
- 235000003497 Eucalyptus tetraptera Nutrition 0.000 description 1
- 241001074693 Eucalyptus torquata Species 0.000 description 1
- 235000013366 Eucalyptus viminalis Nutrition 0.000 description 1
- 240000001414 Eucalyptus viminalis Species 0.000 description 1
- 241000006140 Eucalyptus woodwardii Species 0.000 description 1
- 235000012058 Eugenia apiculata Nutrition 0.000 description 1
- 244000233534 Eugenia apiculata Species 0.000 description 1
- 235000006647 Eugenia jambos Nutrition 0.000 description 1
- PSMFFFUWSMZAPB-UHFFFAOYSA-N Eukalyptol Natural products C1CC2CCC1(C)COCC2(C)C PSMFFFUWSMZAPB-UHFFFAOYSA-N 0.000 description 1
- 241000242711 Fasciola hepatica Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 235000002917 Fraxinus ornus Nutrition 0.000 description 1
- 244000182067 Fraxinus ornus Species 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 241000605952 Fusobacterium necrophorum Species 0.000 description 1
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 description 1
- 201000000628 Gas Gangrene Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000920462 Heterakis Species 0.000 description 1
- 241000638402 Incana Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241001514666 Kunzea Species 0.000 description 1
- 241001514665 Kunzea baxteri Species 0.000 description 1
- 244000165082 Lavanda vera Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 241001469654 Lawsonia <weevil> Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 235000017865 Leptospermum laevigatum Nutrition 0.000 description 1
- 235000003658 Leptospermum petersonii Nutrition 0.000 description 1
- 240000002184 Leptospermum petersonii Species 0.000 description 1
- 241001187390 Leptospermum rotundifolium Species 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 241001185311 Lyticum Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 240000003928 Malus coronaria Species 0.000 description 1
- 241001293418 Mannheimia haemolytica Species 0.000 description 1
- 208000010315 Mastoiditis Diseases 0.000 description 1
- 241000231785 Megacephala Species 0.000 description 1
- 241000378467 Melaleuca Species 0.000 description 1
- 241001264702 Melaleuca armillaris Species 0.000 description 1
- 241001265121 Melaleuca decussata Species 0.000 description 1
- 241001264689 Melaleuca diosmifolia Species 0.000 description 1
- 241001264677 Melaleuca hypericifolia Species 0.000 description 1
- 235000001136 Melaleuca leucadendron Nutrition 0.000 description 1
- 241001264687 Melaleuca styphelioides Species 0.000 description 1
- 241001265117 Melaleuca wilsonii Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241000002163 Mesapamea fractilinea Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241001460362 Metrosideros kermadecensis Species 0.000 description 1
- 241000588622 Moraxella bovis Species 0.000 description 1
- 241000933171 Mosiera Species 0.000 description 1
- 241000513886 Mycobacterium avium complex (MAC) Species 0.000 description 1
- 241000187478 Mycobacterium chelonae Species 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 229930183781 Mycobactin Natural products 0.000 description 1
- 241001138504 Mycoplasma bovis Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 235000017561 Myrtus mucronata Nutrition 0.000 description 1
- 244000038458 Nepenthes mirabilis Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 235000000380 Nyssa aquatica Nutrition 0.000 description 1
- 240000005295 Nyssa aquatica Species 0.000 description 1
- 231100000694 OECD Guidelines for the Testing of Chemicals Toxicity 0.000 description 1
- 241000510960 Oesophagostomum Species 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 241000701019 Ovine gammaherpesvirus 2 Species 0.000 description 1
- 241000252861 Ovine herpesvirus 1 Species 0.000 description 1
- 241000904715 Oxyuris Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000244187 Parascaris Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000517307 Pediculus humanus Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 235000012086 Pimenta racemosa Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000702619 Porcine parvovirus Species 0.000 description 1
- 241000605894 Porphyromonas Species 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 206010037075 Protozoal infections Diseases 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 235000008722 Psidium friedrichsthalianum Nutrition 0.000 description 1
- 244000168576 Psidium friedrichsthalianum Species 0.000 description 1
- 235000015126 Psidium littorale Nutrition 0.000 description 1
- 235000000742 Psidium molle Nutrition 0.000 description 1
- 206010037294 Puerperal pyrexia Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 235000013234 Rhus glabra Nutrition 0.000 description 1
- 235000013831 Rhus typhina Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000277263 Salmo Species 0.000 description 1
- 241000607128 Salmonella enterica subsp. enterica serovar Infantis Species 0.000 description 1
- 241001608490 Salmonella enterica subsp. enterica serovar Liverpool Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241000607694 Serratia odorifera Species 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- KMJLGCYDCCCRHH-UHFFFAOYSA-N Spathulenol Natural products CC1(O)CCC2(C)C1C3C(CCC2=C)C3(C)C KMJLGCYDCCCRHH-UHFFFAOYSA-N 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191980 Staphylococcus intermedius Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000775777 Streptococcus agalactiae ATCC 13813 Species 0.000 description 1
- 241000194042 Streptococcus dysgalactiae Species 0.000 description 1
- 241000194049 Streptococcus equinus Species 0.000 description 1
- 241000122932 Strongylus Species 0.000 description 1
- 244000297179 Syringa vulgaris Species 0.000 description 1
- 235000004338 Syringa vulgaris Nutrition 0.000 description 1
- 244000087016 Syzygium jambos Species 0.000 description 1
- 235000016641 Syzygium paniculatum Nutrition 0.000 description 1
- 244000223082 Syzygium paniculatum Species 0.000 description 1
- 235000012096 Syzygium samarangense Nutrition 0.000 description 1
- 240000004460 Tanacetum coccineum Species 0.000 description 1
- 241001187354 Taxandria juniperina Species 0.000 description 1
- 206010057040 Temperature intolerance Diseases 0.000 description 1
- 241000607216 Toxascaris Species 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 241000244031 Toxocara Species 0.000 description 1
- 241001223089 Tremovirus A Species 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 241001489151 Trichuris Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000571986 Uncinaria Species 0.000 description 1
- 241000202921 Ureaplasma urealyticum Species 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 206010046793 Uterine inflammation Diseases 0.000 description 1
- 241001558516 Varroa destructor Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000544286 Vibrio anguillarum Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 241000607265 Vibrio vulnificus Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 241001148129 Yersinia ruckeri Species 0.000 description 1
- 238000007401 Ziehl–Neelsen staining Methods 0.000 description 1
- ROVGZAWFACYCSP-MQBLHHJJSA-N [2-methyl-4-oxo-3-[(2z)-penta-2,4-dienyl]cyclopent-2-en-1-yl] (1r,3r)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OC1C(C)=C(C\C=C/C=C)C(=O)C1 ROVGZAWFACYCSP-MQBLHHJJSA-N 0.000 description 1
- 241000606834 [Haemophilus] ducreyi Species 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 201000001028 acute contagious conjunctivitis Diseases 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- XUEHVOLRMXNRKQ-KHMAMNHCSA-N alpha cubebene Natural products CC(C)[C@@H]([C@H]12)CC[C@@H](C)[C@]32[C@@H]1C(C)=CC3 XUEHVOLRMXNRKQ-KHMAMNHCSA-N 0.000 description 1
- FAMPSKZZVDUYOS-UHFFFAOYSA-N alpha-Caryophyllene Natural products CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 description 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 1
- KQAZVFVOEIRWHN-UHFFFAOYSA-N alpha-thujene Natural products CC1=CCC2(C(C)C)C1C2 KQAZVFVOEIRWHN-UHFFFAOYSA-N 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 208000006730 anaplasmosis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000884 anti-protozoa Effects 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 238000009341 apiculture Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- IKTRNOZMSJUISH-UHFFFAOYSA-N azulen-4-ol Chemical compound OC1=CC=CC=C2C=CC=C12 IKTRNOZMSJUISH-UHFFFAOYSA-N 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 230000037358 bacterial metabolism Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229940092524 bartonella henselae Drugs 0.000 description 1
- 235000015935 bayrumtree Nutrition 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- BFAKENXZKHGIGE-UHFFFAOYSA-N bis(2,3,5,6-tetrafluoro-4-iodophenyl)diazene Chemical compound FC1=C(C(=C(C(=C1F)I)F)F)N=NC1=C(C(=C(C(=C1F)F)I)F)F BFAKENXZKHGIGE-UHFFFAOYSA-N 0.000 description 1
- 235000000332 black box Nutrition 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000003582 book leaf mallee Nutrition 0.000 description 1
- FOANIXZHAMJWOI-UHFFFAOYSA-N bromopropylate Chemical compound C=1C=C(Br)C=CC=1C(O)(C(=O)OC(C)C)C1=CC=C(Br)C=C1 FOANIXZHAMJWOI-UHFFFAOYSA-N 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000000141 cabbage gum Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 1
- 229940117948 caryophyllene Drugs 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- NNWHUJCUHAELCL-PLNGDYQASA-N cis-isomethyleugenol Chemical compound COC1=CC=C(\C=C/C)C=C1OC NNWHUJCUHAELCL-PLNGDYQASA-N 0.000 description 1
- 235000002655 coarse leaf mallee Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- VLXDPFLIRFYIME-BTFPBAQTSA-N copaene Chemical compound C1C=C(C)[C@H]2[C@]3(C)CC[C@@H](C(C)C)[C@H]2[C@@H]31 VLXDPFLIRFYIME-BTFPBAQTSA-N 0.000 description 1
- BXNANOICGRISHX-UHFFFAOYSA-N coumaphos Chemical compound CC1=C(Cl)C(=O)OC2=CC(OP(=S)(OCC)OCC)=CC=C21 BXNANOICGRISHX-UHFFFAOYSA-N 0.000 description 1
- XUEHVOLRMXNRKQ-HKGGGCDWSA-N cubebene Chemical compound CC(C)[C@H]([C@@H]12)CC[C@H](C)C32C1C(C)=CC3 XUEHVOLRMXNRKQ-HKGGGCDWSA-N 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- PQANGXXSEABURG-UHFFFAOYSA-N cyclohex-2-en-1-ol Chemical compound OC1CCCC=C1 PQANGXXSEABURG-UHFFFAOYSA-N 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000036576 dermal application Effects 0.000 description 1
- 230000007682 dermal toxicity Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- FRMCCTDTYSRUBE-HYFYGGESSA-N ent-spathulenol Chemical compound C1CC(=C)[C@H]2CC[C@@](C)(O)[C@@H]2[C@H]2C(C)(C)[C@H]21 FRMCCTDTYSRUBE-HYFYGGESSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 208000006275 fascioliasis Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 208000010801 foot rot Diseases 0.000 description 1
- 239000002316 fumigant Substances 0.000 description 1
- 238000003958 fumigation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 230000008543 heat sensitivity Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 210000000087 hemolymph Anatomy 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 208000028454 lice infestation Diseases 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000001198 melaleuca alternifolia leaf oil Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000000079 moort Nutrition 0.000 description 1
- XZGYBQIQSLSHDH-COEJQBHMSA-N mycobactin Chemical compound C1CCCN(O)C(=O)C1NC(=O)C(C)C(CC)OC(=O)C(CCCCN(O)C(=O)\C=C/CCCCCCCCCCCCCCC)NC(=O)C(N=1)COC=1C1=C(C)C=CC=C1O XZGYBQIQSLSHDH-COEJQBHMSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 150000007823 ocimene derivatives Chemical class 0.000 description 1
- 231100000204 oral acute (single dose) toxicity testing Toxicity 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000003525 pear fruit mallee Nutrition 0.000 description 1
- PMJHHCWVYXUKFD-UHFFFAOYSA-N penta-1,3-diene Chemical compound CC=CC=C PMJHHCWVYXUKFD-UHFFFAOYSA-N 0.000 description 1
- 238000011886 postmortem examination Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 208000009305 pseudorabies Diseases 0.000 description 1
- 229940015367 pyrethrum Drugs 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 244000222459 red ironbark Species 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 235000003544 round leaf mallee Nutrition 0.000 description 1
- 229930006696 sabinene Natural products 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- AFJYYKSVHJGXSN-KAJWKRCWSA-N selamectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C(/C)=C/C[C@@H](O[C@]2(O[C@@H]([C@@H](C)CC2)C2CCCCC2)C2)C[C@@H]2OC(=O)[C@@H]([C@]23O)C=C(C)C(=N\O)/[C@H]3OC\C2=C/C=C/[C@@H]1C AFJYYKSVHJGXSN-KAJWKRCWSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 229940115939 shigella sonnei Drugs 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 235000002581 silver top gimlet Nutrition 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940115920 streptococcus dysgalactiae Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229930006978 terpinene Natural products 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- XJPBRODHZKDRCB-UHFFFAOYSA-N trans-alpha-ocimene Natural products CC(=C)CCC=C(C)C=C XJPBRODHZKDRCB-UHFFFAOYSA-N 0.000 description 1
- 239000006150 trypticase soy agar Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 101150114434 vanA gene Proteins 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to methods and compositions for preventing or controlling microbial infections or parasitic infestations in animals including mammals, insects, fish, crustaceans and birds.
- microbial infections microbial, fungal and mold infections and parasitic infestations
- farmed animals Land and marine
- beneficial insects such as bees.
- the methods and compositions described herein may also find application in the treatment and control of conditions in wild animals, fish, insects and birds and no limitation is intended thereby.
- Microbial infections including bacterial and viral infections and parasitic infestations by agents such as acarids, protozoans and helminths in farmed animals and birds, beneficial insects, fish and crustaceans such as shrimp can have a significant economic impact on the relevant industries.
- Some conditions are untreatable and the only method of control is by culling.
- Other conditions may be treated with antimicrobial or pesticidal compositions.
- the chemicals used in such treatments leave an unacceptable level of residue in a food product obtained either directly or indirectly from the animal, insect, bird or fish. This either prohibits the use of some active agents or restricts their use to particular window periods in the lifecycle. Further, many strains of infectious agents are becoming resistant to current antibiotics.
- Exemplary conditions caused by infectious agents in animals include pneumonia, otitis media, sinusitus, bronchitis, tonsillitis, and mastoiditis related to infection by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Enterococcus faecalis, E. faecium, E. casselflavus, S. epidermidis, S.
- haemolyticus or Peptostreptococcus spp.
- pharyngitis rheumatic fever, and glomerulonephritis related to infection by Streptococcus pyogenes, Groups C and G streptococci, Corynebacterium diphtheriae, or Actinobacillus haemo lyticum
- respiratory tract infections related to infection by Mycoplasma pneumoniae, Legionella pneumophila, Streptococcus pneumoniae, Haemophilus influenzae, or Chiamydia pneumoniae
- blood and tissue infections including endocarditis and osteomyelitis, caused by S. aureus, S. haemolyticus, E.
- strains resistant to known antibacterials such as, but not limited to, beta-lactams, vancomycin, aminoglycosides, quinolones, chloramphenicol, tetracylines and macrolides; uncomplicated skin and soft tissue infections and abscesses, and puerperal fever related to infection by Staphylococcus aureus, coagulase-negative staphylococci (i.e., S. epidermidis, S.
- Streptococcus pyogenes Streptococcus agalactiae, Streptococcal groups C-F (minute-colony streptococci), viridans streptococci, Corynebacterium minutissimum, Clostridium spp., or Bartonella henselae
- uncomplicated acute urinary tract infections related to infection by Staphylococcus aureus, coagulase-negative staphylococcal species, or Enterococcus spp.
- urethritis and cervicitis sexually transmitted diseases related to infection by Chlamydia trachomatis, Haemophilus ducreyi, Treponema pallidum, Ureaplasma urealyticum, or Neiserria gonorrheae
- aureus food poisoning and toxic shock syndrome
- Groups A, B, and C streptococci ulcers related to infection by Helicobacter pylori, systemic febrile syndromes related to infection by Borrelia recurrentis; Lyme disease related to infection by Borrelia burgdorferi; conjunctivitis, keratitis, and dacrocystitis related to infection by Chlamydia trachomatis, Neisseria gonorrhoeae, S. aureus, S. pneumoniae, S. pyogenes, H.
- MAC Mycobacterium avium complex
- chelonei gastroenteritis related to infection by Campylobacter jejuni; intestinal protozoa related to infection by Cryptosporidium spp.; odontogenic infection related to infection by viridans streptococci; persistent cough related to infection by Bordetella pertussis; gas gangrene related to infection by Clostridium perfringens or Bacteroides spp.; and atherosclerosis or cardiovascular disease related to infection by Helicobacter pylon or Chiamydia pneumoniae.
- a particularly problematic condition which can occur in ruminants is paratuberculosis or Johne's disease.
- This is a contagious bacterial disease of the intestinal tract caused by the bacteria Mycobacterium paratuberculosis.
- the disease is a chronic condition contracted by calves but symptoms do not occur for several years. The disease causes a progressive thickening of the intestine and colon which slowly results in an irreversible loss of weight. There is no existing cure for this condition and infected animals must be slaughtered.
- Parasitic diseases may be caused by either endoparasites or ectoparasites.
- Endoparasites are those parasites which live inside the body of the host, either within an organ (such as the stomach, lungs, heart, intestines, etc.) or simply under the skin.
- Ectoparasites are those parasites which live on the outer surface of the host but still draw nutrients from the host.
- helminthiasis The endoparasitic diseases generally referred to as helminthiasis are due to infection of the host with parasitic worms known as helminths. Helminthiasis is a prevalent and serious worldwide economic problem due to infection of domesticated animals such as swine, sheep, horses, cattle, goats, dogs, cats, and poultry. Many of these infections are caused by the group of worms described as nematodes which cause diseases in various species of animals throughout the world. These diseases are frequently serious and can result in the death of the infected animal.
- the most common genera of nematodes infecting the animals referred to above are Haemonchus, Trichostrongylus, Ostertagia, Nematodirus, Cooperia, Ascaris, Bunostomum, Oesophagostomum, Chabertia, Trichuris, Strongylus, Trichonema, Dictyocaulus, Ca pillaria, Heterakis, Toxocara, Ascaridia, Oxyuris, Ancylostoma, Uncinaria, Toxascaris, and Parascaris. Many parasites are species specific (infect only one host) and most also have a preferred site of infection within the animal.
- Haemonchus and Ostertagia primarily infect the stomach while Nematodirus and Cooperia mostly attack the intestines.
- Other parasites prefer to reside in the heart, eyes, lungs, blood vessels, and the like while still others are subcutaneous parasites.
- Helminthiasis can lead to weakness, weight loss, anaemia, intestinal damage, malnutrition, and damage to other organs. If left untreated these diseases can result in the death of the animal.
- Infections by ectoparasitic arthropods such as ticks, mites, lice, stable flies, hornflies, blowflies, fleas, and the like are also a serious problem. Infection by these parasites results in loss of blood, skin lesions, and can interfere with normal eating habits thus causing weight loss. These infections can also result in transmission of serious diseases such as encephalitis, anaplasmosis, swine pox, and the like which can be fatal.
- Animals may be infected by several species of parasite at the same time since infection by one parasite may weaken the animal and make it more susceptible to infection by a second species of parasite.
- a compound with a broad spectrum of activity is particularly advantageous in the treatment of these diseases.
- Beneficial insects such as bees are also susceptible to infections and infestations which can have a significant commercial effect on the beekeeping industry.
- Bees are subject to infestations by mites such as varroa and acarine mites.
- Varroa mites, Varroa destructor are parasites that feed on the blood of the bees.
- Acarine mites, Acarapis woodi infect the airways of the bee.
- Bees are also subject to bacterial infections such as American foulbrood and European foulbrood. These conditions are caused by bacterial infections of Bacillus larvae and Melisococus pluton respectively.
- American foulbrood is infectious and deadly to bee larvae.
- honeybees there is the further need to ensure that the treatment will not result in unacceptable levels of toxic chemicals in the hive products such as honey, beeswax, pollen, propolis, venom, and the like,
- the poultry industry is yet another industry in which disease can have significant economic impact.
- the economic impact of avian flu has been particularly significant.
- the only treatment available for avian flu is culling.
- a method for the treatment or prophylaxis of a microbial infection in an animal comprising administering to said animal or locus thereof, an antimicrobially effective amount of a composition derived from essential oils of Myrtaceae plants, wherein at least about 85% of the monoterpene content of the oil has been removed.
- a method for the treatment or prophylaxis of a pest infestation in an animal comprising administering to said animal or the locus thereof a pesticidally effective amount of a composition derived from essential oils of a Myrtaceae plant, wherein at least about 85% of the monoterpene content of the oil has been removed.
- animal is to be construed widely as including any suitable animal within the kingdom animalia, and includes vertebrate animal such as mammals, birds and fish and also insects and crustaceans.
- the methods and compositions of the present invention are particularly applicable for the treatment and control of infections or infestations of domestic or agricultural or aquaculture animals.
- compositions of the present invention will be described with particular reference to a composition derived from Melaleuca alternifolia. However, it will be appreciated that compositions of the invention may also be sourced from other Myraceae species and no limitation is intended thereby Other suitable sources of compositions of the present invention include, but are not limited to, M. Bracteata, M. Cricifolia, M. quinquinervia, and others appearing on Table 1, which is hereby incorporated in full by reference.
- Essential oils are complex mixtures of volatile oils produced by plants and are responsible for the odor of many plants.
- the essential oil, once produced, is either released to the environment or stored in oil cells for later use.
- Essential oils stored in the wood of plants serves to deter micro-organisms and insects from attack.
- Essential oils having antiseptic properties are well known.
- the essential oil obtained from the steam distillation of the stems and leaves of Myrtaceae family, of which one is Melaleuca afternifolia, is known as tea tree or Melaleuca oil. It is used widely as a topical antiseptic and in the control of ectoparasites such as fleas and head lice.
- Essential oils contain large amounts of terpenes. Terpenes are classified according to the number of units of the basic structure methylbuta-1,3-diene or isoprene which make up the terpene. Monoterpenes contain two isoprene units and have the chemical formula C 10 H 16 . Terpenes may be acyclic such as myrcene and ocimene or cyclic such as limonene. Typically, commercially available Melaleuca oil comprises up to about 50% monoterpenes. Monoterpenes found in melaleuca oil include alpha-pinene, gamma terpinene, alpha terpinene and limonene.
- Essential oils typically also contain sesquiterpenes. Sesquiterpenes contain three isoprene units and have the general formula C 15 H 24 and are generally found in much lower quantities than the monoterpenes. For example, Melaleuca oil typically contains about 4 to 8% sesquiterpenes.
- Oxidates Another class of compounds commonly found in essential oils are known as oxygenates. These compounds have an oxygen containing functional group. Examples are aldehydes, phenol alcohols, carboxylic acids, ketones and esters.
- Terpin-4-ol having the formula, C 10 H 18 O is a major constituent of Melaleuca oil and can constitute up to 40% of the oil. Terpin-4-ol is considered to be the major active constituent of Melaleuca oil.
- other oxygenated products and the monoterpenes are also believed to have some antimicrobial activity.
- composition of commercially available Melaleuca oils is partially regulated by International and Australian Standards. These standards set a minimum terpin-4-ol content of 30% and a maximum 1,8-cineol content of 15%.
- Terpenes contain double bonds, which are susceptible to oxidation. It is believed that the capacity to generate activated oxygen intermediates may be responsible for their antimicrobial activity. On the other hand, this susceptibility to oxidation results in instability. Terpenes, particularly monoterpenes, are primarily saturated hydrocarbons, which are vulnerable to oxidation by oxygen in the environment surrounding the monoterpenes. The attack occurs in the region of the C—C double bonds of the terpene molecule. Such instability typically leads to discoloration, odor and premature loss of the proactive sites and also accounts for some of the observed heat sensitivity and chemic al reactivity of the essential oils. A further disadvantage is that some of these oxidation products may be irritating or even allergenic.
- the present inventor has surprisingly and unexpectedly discovered that a composition derived from Melaleuca essential oil, whereby a major portion of the monoterpene content has been removed, not only exhibits improved stability but also retains and in some cases increases its antiseptic, antimicrobial and pesticidal properties.
- the present inventor has further observed that a preferred composition of the present invention exhibits improved antimicrobial and pesticidal properties when compared with conventional Melaleuca oil.
- the present inventor has discovered that whilst conventional Melaleuca oil is suitable only for topical administration in view of it's toxicity when ingested, that a preferred composition of the invention may be considered safe for oral administration in animals, birds, fish and insects and further does not leave an undesirable chemical residue in a food obtained from such organisms.
- Toxic effects which may be experienced if after ingestion of commercial Melaleuca oil, include seizures, coma and respiratory depression.
- the essential oil from which the composition is derived may be extracted from any one or more Myrdaceae species.
- the essential oil is extracted from Melaleuca alternifola.
- the essential oil is typically derived by known procedures such as steam distillation.
- essential oils derived from Melaleuca species comprise a monoterpene fraction, an oxygenate fraction and a sesquiterpene fraction, although it will be appreciated that different species may contain different relative amounts of each fraction.
- the monoterpenes are generally the most volatile and have the lowest molecular weight. Thus, they may be removed by techniques known to those of skill in the art including vacuum low temperature techniques such as inert gas flushed distillation; molecular weight separation techniques including chromatographic techniques and selective solvent extraction techniques.
- the monoterpenes are removed under reduced pressure and at a temperature which does not exceed 50° C., preferably 40° C. Typically between about 80 and about 99% of the monoterpenes are removed, typically between about 90 and about 99%.
- a preferred composition for use with the methods of the invention is derived from the essential oil of Melaleuca altemifolia and typically comprises from between about 40 to about 60%, preferably between about 50 to about 55% terpen-4-ol and between about 8 to about 30%, preferably between about 8 to about 25% sesquiterpenes.
- the sesquiterpene fraction may include aromadendrene, voridiflorene, delta cadinene, globulol and/or viridiflorol.
- the antimicrobial composition may find application as an antibacterial, antiprotozoan, antifungal and/or antiviral agent.
- the composition is effective against a broad range of micro-organisms including E. coli, S. aureus, P. aeruginosa, C albicans, S. epidermidis, Penicilium ssp, Cladosporium, A. Niger, A. fumigatus, P. expansum, S. chartarum, Alteraria, Aspergillus, Fusarium, B. subtills, B. cereus, C. perfringens, K. pneumoniae, L. lactis, M. smegmatis, S. marcescens, S. pyogenes, A.
- viridans E. aerogenes, S. liquefaciens, P. vulgaris, S. enteridis, P. mirabills, S. abaetetuba, L. monocytogenes, N. Gonorrhoeae, Legionella, M. Gordanoae and M. catarrhalis and viruses including coronavirus, rotavirus, adenovirus, herpes simplex, papillovirus, rhinovirus, hepatitis B and A, enterovirus and parainfluenza virus.
- Bacterial infections and protozoal infections, and disorders related to such infections, which may be treated or prevented in animals, birds, fish and insects, include the following: bovine respiratory disease related to infection by P. haemolytica, P. multocida, Mycoplasma bovis, or Bordetella spp.; cow enteric disease related to infection by E. coli or protozoa (i.e., coccidia, cryptosporidia, etc.); dairy cow mastitis related to infection by S. aureus, Strep.
- uberis Streptococcus agalactiae, Streptococcus dysgalactiae, Corynebacterdum, or Enterococcus spp.
- swine respiratory disease related to infection by A. pleuro., P. multocida, or Mycoplasma spp.
- swine enteric disease related to infection by E.
- cow footrot related to infection by Fusobacterium spp.
- cow metritis related to infection by E coli
- cow hairy warts related to infection by Fusobacterium necrophorum or Bacteroides nodosus
- cow pink-eye related to infection by Moraxella bovis
- cow premature abortion related to infection by protozoa (i.e. neosporium); urinary tract infection in dogs and cats related to infection by E. coli; skin and soft tissue infections in dogs and cats related to infection by S. epidermidis, S. intermedius, coagulase neg. Staphylococcus or P.
- Viral infections and disorders associated with such infections which may be treated or prevented in animals and birds include the following: bovine herpesvirus 1-5 (BHV), ovine herpesvirus 1 and 2, Canine herpesvirus 1, equine herpesvirus 1-8 (EHV), feline herpesvirus 1 (FHV), and pseudorabies virus (PRV), porcine herpesvirus (PRV) or Aujeszky's disease (pseudorabies virus or PRV), the porcine reproductive respiratory syndrome virus (or PRRSV), the swine influenza virus (SIV), the conventional hog cholera virus (or HCV), parvoviruses in porcines, bovine respiratory syncitial virus (BRSV), bovine diarrhoea virus (BVDV), porcine reproductive respiratory syndrome virus (PRRSV), swine influenza virus (SIV), rabies virus, hog cholera virus, porcine parvoviruses (HCV), herpesvirus of turkeys (HVT), Infectious Bovine
- the present invention also relates to a method of controlling a pest infestation in an animal, bird, fish or insect.
- Pests which may be controlled include ecto and endoparasites.
- Examples of pests which may be controlled by the method of the present invention include gastrointestinal worms such as liver fluke, hookworm, heartworm whipworm and tapeworm; ticks, mites, lice and flies.
- the composition may be in any suitable form and for internal or external use.
- Preparations for internal use include powders, tablets, dispersible granules capsules, solutions, suspensions, and emulsions suitable for oral ingestion or injection.
- the composition is provided in the form of a food supplement which may be added to an animal's food or water supply.
- composition may also find use as a topical anti-microbial and/or anti-parasitic agent.
- topical anti-microbial and/or anti-parasitic agent examples include antiseptic scrubs or washes and flea and lice shampoos, spray, plunge dips and pur-on formulations.
- the topical compositions may also be administered in the form of wound dressings, transdermal patches and the like.
- wound dressings are impregnated with a composition of the invention at a concentration of active agents of between about 10000 to about 5000 ppm.
- composition may be applied in the form of an aerosol.
- aerosol Such formulations may be used for the treatment of lung infections.
- effective dosing may be determined in accordance with the disease and the level of infection encountered. As some examples only, and without limitation, if the disease is detected early in the infection, one may use doses of between 5-10 mg per kilo body weight. If the disease is detected when the infection has taken a strong hold, one may use between 50-100 mg per kilo body weight. As a prophylactic dose to prevent disease, i.e. influenza, one may use dose levels of 1-5 mg per kilo body weight.
- the composition may also be applied to the locus of an animal, fish, bird or fish. Where the composition is used to treat infections and infestation in fish the composition may also be in the form of an additive which may be added to the water in a fish or holding tank.
- composition may also be used in the form of a fumigant for the purposes of controlling infectious agents in an animal enclosure such as a dairy, stable, pen or the like.
- a particular application is the fumigation or fogging of bee hives to control or treat mite infestations.
- Table 2 describes further treatment details and methods that comprise some embodiments of the invention.
- base composition means the composition of Example 3 below or reasonable equivalents thereof.
- the plants are harvested from a field by cutting the scrubs off just above ground level. They are mulched and placed into a steel trailer-like transport vessel. The trailer is brought into a distillation shed. Steam is pushed through the mulched wood and leaf mix, and water and oil is collected via a stainless steel condenser. The oil is centrifuged out of the water oil mix and collected. The oil is then cleaned up and concentrated for the final product.
- essential oil from Melaleuca alternifolia oil has the following characteristics:
- some embodiments of the invention comprise a composition prepared by removing essentially all the monoterpene fraction from Melaleuca altemifola essential oil.
- the composition of said oil after removal of the monoterpene fraction is about as follows:
- Test Results Weight Compound PerCent* CAS No. Para cymene 0.34 000535-77-3 Alph Terpinene 1.15 000099-85-4 Linalool 0.37 029050-33-7 2-cycohexen-1-ol,1-methyl- 0.27 029803-82-5 4-1(1-methyethyl)-,cis 2/cyclohexen-1-ol,1-methyl-4- 0.68 029803-81-4 91-methylethyl 2-cylohexan-1-ol,methyl- 0.53 029803-82-5 4-(1-methylethyl)-cis Terpinene-4-ol 48.90 000562-74-3 Alpha terpineol 9.04 000098-55-5 2-cyclohexen-1-ol,3-methyl- 0.49 016721-38-3 6-(1-m-ethylethyl)-cis Cyclohexanol,2,3,5- 0.41 000116-02-9 trimethyl 2,
- the fogger delivered about 10 to 30 micron droplets of 1% base composition solution, with about 2 liters per 25,000 birds per spray. All parts of the animal storage shed were sprayed as well as the birds so that they inhale the test solution into their systems, so offering not only a virus free environment but also the base composition transferred into the blood system via the lungs of the growing birds.
- the sheds and litter were fogged prior to the birds being placed in the sheds or in the case of established sheds, the birds are fogged daily for the first week and then weekly.
- the virus H5N1 was grown in fertile eggs titer established and then by serial dilution made into the following concentrations of virus:
- Combining a fogging system at 1% base composition in the sheds to kill or reduce virus and other bacteria should contain all infections both viral and bacterial and without the use of antibodies. This would have the added advantage of speeding up the growth time of the birds, and improve the turn round time in the sheds, with cost-effective reduction in feed, use and housing time, and the like.
- the antimicrobial activity of a composition comprising some embodiments of the invention was examined.
- the base composition was tested using a 96-well microtiter tray and the concentrations of the base composition were in the range of about 2-0.0025%.
- Food pathogens were prepared in double-strength Mueller Hinton broth, resulting in the organisms at final concentrations between 1.5 ⁇ 10 5 -2.5 ⁇ 10 6 cfu/ml. Tests were incubated at 35° C. for 24 hours and subcultured by removing 10 microliters from tray wells and spot inoculating onto blood agar. All subcultures were incubated and the colonies counted.
- the minimum inhibitory concentration (“MIC”) was defined as the lowest concentration of product resulting in the maintenance or reduction of the inoculum.
- MCC minimum cidal concentration
- the tests were carried out twice. If discrepant results were obtained, a third test was conducted.
- the MlCs of strains of Campylobacter jejuni were determined by agar dilution using Mueller Hinton Agar containing 5% lysed horse blood.
- the inocula were prepared in 0.85% saline and a volume of 10 ul/spot was applied onto the MHA plates. The final concentration was approximately 5 ⁇ 105 ⁇ 1 Os cfu/spot. All results were read after 48 h of incubation in a 37° C. in a microaerophilic atmosphere (5% 02, 10% CO2, 85% N2). The MIC was defined as the lowest giving complete inhibition of visible growth. See Table 3 below for results.
- composition comprising some embodiments of the invention was tested, starting at 10% base concentration, against 20 clinical isolates.
- VRE Vancomycin resistant Enterococcus faecium and faecalis
- golden staph bacteria were inhibited at 0.12% base composition; VRE bacteria were inhibited at 1% concentration of base composition; and ESBL bacteria were inhibited at 0.5% concentration of base composition.
- One embodiment was tested against 20 clinical isolates of multi-resistant methicillin resistant Staphylococcus aureus using agar dilution techniques.
- the tested concentrations initially were 0.03% and 0.06% base composition. All 24 clinical strains including ATCC controls grew at both concentrations, Agar dilution testing was repeated using additional concentrations ranging from 0.015% to 2% base composition. Secondary testing was performed.
- a 10% solution of the base composition was tested against 20 clinical isolates of the vancomycin resistant Enterococcus species using an agar dilution technique.
- Mycobacterium avium subspecies paratuberculosis ( M. paratuberculosis ) is a very slow growing mycobactin dependent mycobacterial species known to be the causative agent of Johne's disease ( paratuberculosis ) in all species of domestic ruminants.
- the bacteriostatic activity (growth inhibition) of the base composition was tested on following mycobacteria:
- M. paratuberculosis strains CLIJ62, CLIJ748, ATTCJ9698—slow growing mycobacterial species with lengthy growth period in vitro on solid based laboratory media and a more rapid growth cycle in a selective broth environment;
- M. avium (strain D4)—a moderate growing mycobacterial species
- the BACTECTM 460 radiometric system is a well established semi-automated broth-based culture system procedure that provides rapid detection of M. paratuberculosis.
- the BACTEC procedure for antimicrobial susceptibility testing of mycobacteria is based on the same basic principal used in the conventional method: for bacterial propagation a liquid medium is used instead of counting colonies after a long incubation period, the growth is monitored radiometrically, and results are reportable within a shorter time frame.
- the amount of 14 CO 2 released from 14 C-labelled substrate reflects the rate and amount of growth occurring in the vial and is expressed in terms of the “Growth Index” (“GI”).
- GI Crowth Index
- Resistant when was not affected during the course of experiment.
- the bacteriostatic activity (“growth inhibitions) of the base composition for mycobacteria in the active phase of growth was evaluated in vitro using the BACTEC 460 radiometric culture system using three concentrations of base composition solution supplied.
- the MICs determined for M. paraetuberculosis, M. avium and M. smegmatis were 0.1%; 0 125% r and 0.15% base composition. Growth inhibition was dependent on the inoculum size, source, growth rate and incubation period. We concluded that:
- the base composition is able to affect the bacterial metabolism of all three mycobacteria species tested at concentrations low as 1% of the 10% base composition solution;
- growth inhibition depends on the activity of the inoculum, the rate of growth and the incubation period.
- the acute oral toxicity of the base composition was investigated in 4 Sprague Dawley Specific Pathogen Free (“SPF”) rats at doses of 500 and 1000 ppm base composition at 10 mL/kg.
- SPF Sprague Dawley Specific Pathogen Free
- the experimental procedure was based on OECD guidelines for the testing of chemicals No. 401.
- test solution was administered orally once to 2 pairs of rats at the above doses.
- a third group was administered the vehicle only, solubilized vitamin E solution.
- the equivalent volumetric dose was 10 ml/kg for all groups.
- Body weights were determined immediately before test item administration and at sacrifice on day 8. All animals were observed at frequent intervals on the day of test item administration and then daily for signs of toxicity over the 7 day experimental period, at the end of the experimental period, all animals were sacrificed and subjected to a gross necroscopy examination.
- Results showed that no mortalities were observed during the study; no clinical abnormalities were observed for the duration of the study in any of the treated or control animals; and there were no gross abnormalities noted in the major organs of any animal at necroscopy. Further analysis was carried out by gas chromatography testing of the kidneys and livers. No traces of the components of the base composition were found, indicating that all compounds are successfully excreted from the body.
- the base composition up to the highest doses tested 1000 ppm at 10 ml/kg, did not produce toxicity in the Sprague Dawley rat. These results may be compared to tea tree oil which has been reported to have an LD 50 of 1.9-2.6 ml/kg.
- Acute oral toxicity testing in rats revealed no signs of toxicity at tested levels.
- the acute oral toxicity of 10% solution of base composition was investigated in groups of 2 Sprague Dawley Specific Pathogen Free (SPF) rats at a single dose level.
- the test solution was administered orally by intragastric gavage to one (1) group of 2 rats (1/sex) at the maximum administrable volume of 10 mL/kg.
- a control group of 2 rats (1/sex) was dosed with the vehicle alone (water).
- Body weights were determined immediately before test item administration and daily thereafter. All animals were observed at frequent intervals on the day of test item administration, and then daily for signs of toxicity over the 7-day experimental period. At the end of the experimental period, on Day 8, all surviving animals were sacrificed and subjected to a gross necropsy examination.
- Groups 1 and 3 were treated with a 5%, 15%, and 25% formulation of base composition.
- Group 4 received treatment with 100% base composition and served as an extreme positive control.
- Group 5 received the vehicle, consisting of a specifically formulated Vitamin E base and served as a primary negative control.
- Treatment was administered via a treated gauze pad containing 2 ml of the test substance applied directly to a 2 cm square shaved are on the dorsum of each guinea pig. This provided a direct application of 1 ml/cm 2 .
- the five male guinea pigs were additional to Group 3 and met the requirement of having on test a group of alternate sex subjects receiving the MTD/MDL dose.
- MacFarland Standard concentration of micro organism, etc.
- the MacFarland turbidity standard system was used to estimate the level of bacteria in a solution by the opacity of the liquid against a known MacFarland tube purchased from a biological supplier
- the efficacy of the base composition in inactivating H5N1 virus in an egg test environment was tested. Work was done to confirm the ability of the base composition to act as a virucidal agent against a Vietnamese H5N1 highly pathogenic avian influenza virus strain.
- a 10% solution of the base composition (Batch 020405) was made in dimethyl sulphoxide (DMSO) by adding 1.0 ml of base composition to 9.0 ml of DMSO and mixing thoroughly.
- DMSO dimethyl sulphoxide
- a solution of 1% base composition with no emulsifiers (Batch 102034) was supplied (NeuMedix Ltd, Underwood, Queensland, Australia) and used as supplied for virus treatment.
- the virus was A/chicken/Vietnam/8/2004 H5N1 grown in the allantoic sac of embryonated, SPF chicken eggs. Infectious allantoic fluid was harvested, pooled and stored at ⁇ 80° C. for this trial. The microstores pool reference number of this material is 0404-30-1550.
- the 10% base composition was diluted 1:5, 1.3.3 and 1:2.5 in phosphate buffered saline (pH 7.3) to give final concentrations of 2%, 3% and 4% respectively.
- 0.1 ml of virus was mixed with 0.4 ml of base composition at concentrations of 2%, 3% and 4%.
- Mock-treated virus consisting of 0.1 ml of virus mixed with 0.4 ml of a 1:5 dilution of DMSO without added base composition in PBS
- untreated virus consisting of 0.1 ml of virus mixed with 0.4 ml of PBS, were also prepared. All mixtures were incubated at room temperature for the respective times.
- 2%, 3% and 4% base composition solutions were diluted 1:10 in PBS and 0.1 ml inoculated into 5 eggs each.
- Residual virus was assayed by making 10-fold dilutions in PBS of each virus mixture from 10 ⁇ 1 to 10 ⁇ 8 0.02 ml of virus mixture was added to 1.8 ml of PBS and mixed thoroughly to give a 10 ⁇ 1 dilution. 0.2 ml of this was added to 1.8 ml of PBS and mixed thoroughly to give a 10 ⁇ 2 dilution and so on to a final dilution of 10 ⁇ 8 0.01 ml of each dilution was inoculated into the allantoic sac of embryonated, SPF chicken eggs, incubated at 37° C. for 3 days or until embryo death. Eggs were examined twice daily for viability. At death or after 3 days incubation all eggs were chilled overnight at 4° C. and then tested for the presence of hemagglutination and an indicator of virus infection. The residual infectivity tire was calculated by the method of Reed, and Meunch.
- the base composition can inactivate between 0.3 and 7.1 log 10 of H5N1 avian influenza virus depending on the base composition concentration and contact time between the virus and base composition.
- a 7.1 log 10 inactivation means that all virus was killed. Eggs inoculated with base composition solutions alone showed no egg deaths.
- Mock-treated virus consisting of 0.1 ml of virus mixed with 0.4 ml of a 1:5 dilution of DMSO without added base composition in PBS and untreated virus, consisting of 0.1 ml of virus mixed with 0.4 ml of PBS, were also prepared. All mixtures were incubated (three hours, 180 mins) at room temperature for the respective times. Concentrations and times were selected in accordance with experience from previous experiments.
- the surface membrane incorporates various viral proteins and support the surface projections (which are required for infection of host cells) whilst encompassing the viral nucleic acid (nucleocapsid) which is required for replication.
- the ultrastructural changes could be the inference that they are consistent with the data in Table 4 which show a substantial rise in viral inactivation when H5N1 is exposed to a 4% concentration of base concentration for a contact time of greater than 120 mins.
- Treatment with the inventive composition reduced the mite infestation level to about 1 mite per 50 bees.
- composition of the present invention is superior to current methods of varroa mite control in bee hives.
- a honey bee colony will be selected with at least 50 varroa mites per 300 bees. Approximately 300 bees will be placed in each of 30 metal cages (105 ⁇ 100 ⁇ 40 mm with mesh on one side and glass on the other. Honey will be provided on the floor of the cage on an upturned lid. Additional food will be provided in the form of 2M sugar syrup.
- the base composition will be mixed with food grade mineral oil at 500 and 1000 ppm. This will then be applied to the bees through the mesh on the cage using a fogger. Each treatment and rate will be replicated ten times. The actual application amount will be calculated by weighing the cages before and after fogging.
- the number of mites to fall to the bottom of the cages will be counted after 4, 24 and 48 hours. After 48 hours, the bees w ill be removed, counted and washed in alcohol to remove any live mites.
- EFB European foul brood
- Base composition 0.1% Base carrier Canola oil 99.9% Delivery System Liquid Canola Oil Delivery Load 1 ml per kilo/body weight 5.
- Disease Blood and tissue Infections including the following: Endocarditis, S. auerus , S hamolyticus , E fascalis Osteomyelitis , E durans , beta-lactams vancomycin.
- Formulation Base composition 0.10% Base carrier saline water 99.89 Vitamin E 0.01% Delivery System Intravenous Injection Delivery Load 1 ml per kilo body weight 6.
- Formulation Base composition 1.0% Base Carrier water 98.9% Vitamin E 0.1% Delivery System Capsule 1 gram Delivery Load 1 Capsule per 10 kilo body weight 8. Disease Infections by ectoparasitic arthropods such as ticks, mites, lice, stable flies, hornflies, blowflies, fleas.
- Formulation Base composition 2.0% Base Carrier Soy Oil 98.0% Delivery System Spray-Gels-Creams 9. Disease Avian Influenza Formulation Base composition 0.02% Water 99.96% Vitamin 0.002% Delivery System Drinking water Prevention System Delivery Load As required: Chick will drink twice what they eat a day
Abstract
The invention comprises compositions and methods for the treatment or prophylaxis of a microbial, fungal, or mold infection in an animal, comprising the administration of a composition derived from the essential oil of a Myrtaceae plant, wherein at least about 85% of the monoterpene content of the oil has been removed, in an amount effective to prevent, reduce or eliminate the microbial, fungal, or mold infection.
Description
- This application claims priority from U.S. Provisional Patent Application No. 60/831,413, filed Jul. 17, 2006, which is hereby incorporated in full.
- The present invention relates to methods and compositions for preventing or controlling microbial infections or parasitic infestations in animals including mammals, insects, fish, crustaceans and birds.
- The present invention will be described with particular reference to the control and/or treatment of microbial, fungal and mold infections and parasitic infestations (collectively “microbial infections,” unless otherwise indicated by context) of farmed animals (land and marine), birds and beneficial insects such as bees. However, it will be appreciated that the methods and compositions described herein may also find application in the treatment and control of conditions in wild animals, fish, insects and birds and no limitation is intended thereby.
- Microbial infections including bacterial and viral infections and parasitic infestations by agents such as acarids, protozoans and helminths in farmed animals and birds, beneficial insects, fish and crustaceans such as shrimp can have a significant economic impact on the relevant industries. Some conditions are untreatable and the only method of control is by culling. Other conditions may be treated with antimicrobial or pesticidal compositions. However, in many cases, the chemicals used in such treatments leave an unacceptable level of residue in a food product obtained either directly or indirectly from the animal, insect, bird or fish. This either prohibits the use of some active agents or restricts their use to particular window periods in the lifecycle. Further, many strains of infectious agents are becoming resistant to current antibiotics.
- Exemplary conditions caused by infectious agents in animals include pneumonia, otitis media, sinusitus, bronchitis, tonsillitis, and mastoiditis related to infection by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Enterococcus faecalis, E. faecium, E. casselflavus, S. epidermidis, S. haemolyticus, or Peptostreptococcus spp.; pharyngitis, rheumatic fever, and glomerulonephritis related to infection by Streptococcus pyogenes, Groups C and G streptococci, Corynebacterium diphtheriae, or Actinobacillus haemo lyticum; respiratory tract infections related to infection by Mycoplasma pneumoniae, Legionella pneumophila, Streptococcus pneumoniae, Haemophilus influenzae, or Chiamydia pneumoniae; blood and tissue infections, including endocarditis and osteomyelitis, caused by S. aureus, S. haemolyticus, E. faecalis, E. faecium, E. durans, including strains resistant to known antibacterials such as, but not limited to, beta-lactams, vancomycin, aminoglycosides, quinolones, chloramphenicol, tetracylines and macrolides; uncomplicated skin and soft tissue infections and abscesses, and puerperal fever related to infection by Staphylococcus aureus, coagulase-negative staphylococci (i.e., S. epidermidis, S. hemolyticus, etc.), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcal groups C-F (minute-colony streptococci), viridans streptococci, Corynebacterium minutissimum, Clostridium spp., or Bartonella henselae; uncomplicated acute urinary tract infections related to infection by Staphylococcus aureus, coagulase-negative staphylococcal species, or Enterococcus spp.; urethritis and cervicitis; sexually transmitted diseases related to infection by Chlamydia trachomatis, Haemophilus ducreyi, Treponema pallidum, Ureaplasma urealyticum, or Neiserria gonorrheae; toxin diseases related to infection by S. aureus (food poisoning and toxic shock syndrome), or Groups A, B, and C streptococci; ulcers related to infection by Helicobacter pylori, systemic febrile syndromes related to infection by Borrelia recurrentis; Lyme disease related to infection by Borrelia burgdorferi; conjunctivitis, keratitis, and dacrocystitis related to infection by Chlamydia trachomatis, Neisseria gonorrhoeae, S. aureus, S. pneumoniae, S. pyogenes, H. influenzae, or Listeria spp.; disseminated Mycobacterium avium complex (MAC) disease related to infection by Mycobacterium avium, or Mycobacterium intracellular; infections caused by Mycobacterium tuberculosis, M. leprae, M. paratuberculosis, M. kansasii or M. chelonei; gastroenteritis related to infection by Campylobacter jejuni; intestinal protozoa related to infection by Cryptosporidium spp.; odontogenic infection related to infection by viridans streptococci; persistent cough related to infection by Bordetella pertussis; gas gangrene related to infection by Clostridium perfringens or Bacteroides spp.; and atherosclerosis or cardiovascular disease related to infection by Helicobacter pylon or Chiamydia pneumoniae.
- A particularly problematic condition which can occur in ruminants is paratuberculosis or Johne's disease. This is a contagious bacterial disease of the intestinal tract caused by the bacteria Mycobacterium paratuberculosis. The disease is a chronic condition contracted by calves but symptoms do not occur for several years. The disease causes a progressive thickening of the intestine and colon which slowly results in an irreversible loss of weight. There is no existing cure for this condition and infected animals must be slaughtered.
- Parasitic diseases may be caused by either endoparasites or ectoparasites. Endoparasites are those parasites which live inside the body of the host, either within an organ (such as the stomach, lungs, heart, intestines, etc.) or simply under the skin. Ectoparasites are those parasites which live on the outer surface of the host but still draw nutrients from the host.
- The endoparasitic diseases generally referred to as helminthiasis are due to infection of the host with parasitic worms known as helminths. Helminthiasis is a prevalent and serious worldwide economic problem due to infection of domesticated animals such as swine, sheep, horses, cattle, goats, dogs, cats, and poultry. Many of these infections are caused by the group of worms described as nematodes which cause diseases in various species of animals throughout the world. These diseases are frequently serious and can result in the death of the infected animal. The most common genera of nematodes infecting the animals referred to above are Haemonchus, Trichostrongylus, Ostertagia, Nematodirus, Cooperia, Ascaris, Bunostomum, Oesophagostomum, Chabertia, Trichuris, Strongylus, Trichonema, Dictyocaulus, Ca pillaria, Heterakis, Toxocara, Ascaridia, Oxyuris, Ancylostoma, Uncinaria, Toxascaris, and Parascaris. Many parasites are species specific (infect only one host) and most also have a preferred site of infection within the animal. Thus Haemonchus and Ostertagia primarily infect the stomach while Nematodirus and Cooperia mostly attack the intestines. Other parasites prefer to reside in the heart, eyes, lungs, blood vessels, and the like while still others are subcutaneous parasites. Helminthiasis can lead to weakness, weight loss, anaemia, intestinal damage, malnutrition, and damage to other organs. If left untreated these diseases can result in the death of the animal.
- Infections by ectoparasitic arthropods such as ticks, mites, lice, stable flies, hornflies, blowflies, fleas, and the like are also a serious problem. Infection by these parasites results in loss of blood, skin lesions, and can interfere with normal eating habits thus causing weight loss. These infections can also result in transmission of serious diseases such as encephalitis, anaplasmosis, swine pox, and the like which can be fatal.
- Animals may be infected by several species of parasite at the same time since infection by one parasite may weaken the animal and make it more susceptible to infection by a second species of parasite. Thus, a compound with a broad spectrum of activity is particularly advantageous in the treatment of these diseases.
- Beneficial insects such as bees are also susceptible to infections and infestations which can have a significant commercial effect on the beekeeping industry. Bees are subject to infestations by mites such as varroa and acarine mites. Varroa mites, Varroa destructor are parasites that feed on the blood of the bees. Acarine mites, Acarapis woodi, infect the airways of the bee. Bees are also subject to bacterial infections such as American foulbrood and European foulbrood. These conditions are caused by bacterial infections of Bacillus larvae and Melisococus pluton respectively. American foulbrood is infectious and deadly to bee larvae.
- Referring to treatment of mite infestation in bees, it has been known to use a variety of chemicals to fumigate the bee colonies, or to place certain other compounds therein to try to eliminate the mites from the hive where the colony resides, Among such materials are menthol, formic acid, bromopropylate, Coumaphos, pyrethrum extracts (both naturally occurring and synthetic types) and the like.
- While generally useful, all of these compositions and techniques are not effective for a variety of reasons. One of the problems is that certain of these compounds, such as menthol and formic acid, when placed in the hive adversely affect the behavior of the bees. Because of their strong odor, the bees have an aversion to them and make every effort to remove them from the hive, With other compounds the bees must be removed from the hive, the hive treated, and the bee colony then returned after a period of several weeks. This is a costly and time-consuming process. Also, formic acid is corrosive and difficult and dangerous to handle. Moreover, certain of these compounds are only effective in warm weather conditions. This is particularly true with menthol, which requires at least two weeks of warm weather to cause it to vaporize in order to be effective. In many areas of t he world this is a condition that does not exist throughout the year and, thus, is not effective.
- Moreover, with certain miticides it is difficult to cause the bees to ingest the same and this is particularly a problem in trying to treat tracheal mites residing in the trachea of the bees. If they cannot ingest the miticide to place it into their hemolymph, then the miticide will not be effective.
- In addition to possible aversion to the treatment agent, there is also the problem of the need of high levels of usage which can have adverse effects on the beneficial insect. Here again, there is the need to ensure insect intake of the treatment agent, while at the same time minimizing the amount of agent used to minimize, and preferably eliminate, possible adverse effects.
- In the case of honeybees, there is the further need to ensure that the treatment will not result in unacceptable levels of toxic chemicals in the hive products such as honey, beeswax, pollen, propolis, venom, and the like,
- Another industry where conditions associated with infections and infestations can have significant economic impact is the aquaculture industry. The use of conventional antimicrobial and anti-parasitic compounds with fish and shrimp is that the build up of an unacceptable level of residue in the animal. Some conditions such as bacterial kidney disease and liver disease in salmon are effectively untreatable.
- The poultry industry is yet another industry in which disease can have significant economic impact. The economic impact of avian flu has been particularly significant. The only treatment available for avian flu is culling.
- It is therefore one object of the present invention to provide compositions and methods for treating or preventing infections and infestations in an animal, fish, bird or insect.
- According to a first broad form of some embodiments of the invention, without limitation, there is provided a method for the treatment or prophylaxis of a microbial infection in an animal, the method comprising administering to said animal or locus thereof, an antimicrobially effective amount of a composition derived from essential oils of Myrtaceae plants, wherein at least about 85% of the monoterpene content of the oil has been removed.
- According to a further broad form of some embodiments of the invention, without limitation, there is provided a method for the treatment or prophylaxis of a pest infestation in an animal, the method comprising administering to said animal or the locus thereof a pesticidally effective amount of a composition derived from essential oils of a Myrtaceae plant, wherein at least about 85% of the monoterpene content of the oil has been removed.
- Other aspects of the invention will be apparent to those skilled in the art after reviewing the drawings and the detailed description below.
- In the present specification and claims, the term animal is to be construed widely as including any suitable animal within the kingdom animalia, and includes vertebrate animal such as mammals, birds and fish and also insects and crustaceans. The methods and compositions of the present invention are particularly applicable for the treatment and control of infections or infestations of domestic or agricultural or aquaculture animals.
- The methods and compositions of the present invention will be described with particular reference to a composition derived from Melaleuca alternifolia. However, it will be appreciated that compositions of the invention may also be sourced from other Myraceae species and no limitation is intended thereby Other suitable sources of compositions of the present invention include, but are not limited to, M. Bracteata, M. Cricifolia, M. quinquinervia, and others appearing on Table 1, which is hereby incorporated in full by reference.
- Essential oils are complex mixtures of volatile oils produced by plants and are responsible for the odor of many plants. The essential oil, once produced, is either released to the environment or stored in oil cells for later use. Essential oils stored in the wood of plants serves to deter micro-organisms and insects from attack.
- Due to its being based on essential oils, its biofilm dissolving capacity has been established against Staphylococcus epidermidis, and its cidal effect against MRSA in vitro). We believe the broadband activity is due to all of these factors acting in unison to effectively dissolve biofilm, penetrate bacterial cell walls and then lyses, the bacteria (Mycobacterium tuberculosis).
- Essential oils having antiseptic properties are well known. The essential oil obtained from the steam distillation of the stems and leaves of Myrtaceae family, of which one is Melaleuca afternifolia, is known as tea tree or Melaleuca oil. It is used widely as a topical antiseptic and in the control of ectoparasites such as fleas and head lice.
- Essential oils contain large amounts of terpenes. Terpenes are classified according to the number of units of the basic structure methylbuta-1,3-diene or isoprene which make up the terpene. Monoterpenes contain two isoprene units and have the chemical formula C10H16. Terpenes may be acyclic such as myrcene and ocimene or cyclic such as limonene. Typically, commercially available Melaleuca oil comprises up to about 50% monoterpenes. Monoterpenes found in melaleuca oil include alpha-pinene, gamma terpinene, alpha terpinene and limonene.
- Essential oils typically also contain sesquiterpenes. Sesquiterpenes contain three isoprene units and have the general formula C15H24 and are generally found in much lower quantities than the monoterpenes. For example, Melaleuca oil typically contains about 4 to 8% sesquiterpenes.
- Another class of compounds commonly found in essential oils are known as oxygenates. These compounds have an oxygen containing functional group. Examples are aldehydes, phenol alcohols, carboxylic acids, ketones and esters. Terpin-4-ol, having the formula, C10H18O is a major constituent of Melaleuca oil and can constitute up to 40% of the oil. Terpin-4-ol is considered to be the major active constituent of Melaleuca oil. However, other oxygenated products and the monoterpenes are also believed to have some antimicrobial activity.
- The composition of commercially available Melaleuca oils is partially regulated by International and Australian Standards. These standards set a minimum terpin-4-ol content of 30% and a maximum 1,8-cineol content of 15%.
- Terpenes contain double bonds, which are susceptible to oxidation. It is believed that the capacity to generate activated oxygen intermediates may be responsible for their antimicrobial activity. On the other hand, this susceptibility to oxidation results in instability. Terpenes, particularly monoterpenes, are primarily saturated hydrocarbons, which are vulnerable to oxidation by oxygen in the environment surrounding the monoterpenes. The attack occurs in the region of the C—C double bonds of the terpene molecule. Such instability typically leads to discoloration, odor and premature loss of the proactive sites and also accounts for some of the observed heat sensitivity and chemic al reactivity of the essential oils. A further disadvantage is that some of these oxidation products may be irritating or even allergenic.
- The present inventor has surprisingly and unexpectedly discovered that a composition derived from Melaleuca essential oil, whereby a major portion of the monoterpene content has been removed, not only exhibits improved stability but also retains and in some cases increases its antiseptic, antimicrobial and pesticidal properties. The present inventor has further observed that a preferred composition of the present invention exhibits improved antimicrobial and pesticidal properties when compared with conventional Melaleuca oil. Further still, the present inventor has discovered that whilst conventional Melaleuca oil is suitable only for topical administration in view of it's toxicity when ingested, that a preferred composition of the invention may be considered safe for oral administration in animals, birds, fish and insects and further does not leave an undesirable chemical residue in a food obtained from such organisms. Toxic effects, which may be experienced if after ingestion of commercial Melaleuca oil, include seizures, coma and respiratory depression.
- The essential oil from which the composition is derived may be extracted from any one or more Myrdaceae species. Preferably the essential oil is extracted from Melaleuca alternifola. The essential oil is typically derived by known procedures such as steam distillation.
- As discussed above, essential oils derived from Melaleuca species comprise a monoterpene fraction, an oxygenate fraction and a sesquiterpene fraction, although it will be appreciated that different species may contain different relative amounts of each fraction. Of these fractions, the monoterpenes are generally the most volatile and have the lowest molecular weight. Thus, they may be removed by techniques known to those of skill in the art including vacuum low temperature techniques such as inert gas flushed distillation; molecular weight separation techniques including chromatographic techniques and selective solvent extraction techniques. Prefer ably, the monoterpenes are removed under reduced pressure and at a temperature which does not exceed 50° C., preferably 40° C. Typically between about 80 and about 99% of the monoterpenes are removed, typically between about 90 and about 99%.
- A preferred composition for use with the methods of the invention is derived from the essential oil of Melaleuca altemifolia and typically comprises from between about 40 to about 60%, preferably between about 50 to about 55% terpen-4-ol and between about 8 to about 30%, preferably between about 8 to about 25% sesquiterpenes. The sesquiterpene fraction may include aromadendrene, voridiflorene, delta cadinene, globulol and/or viridiflorol.
- The antimicrobial composition may find application as an antibacterial, antiprotozoan, antifungal and/or antiviral agent. Typically, the composition is effective against a broad range of micro-organisms including E. coli, S. aureus, P. aeruginosa, C albicans, S. epidermidis, Penicilium ssp, Cladosporium, A. Niger, A. fumigatus, P. expansum, S. chartarum, Alteraria, Aspergillus, Fusarium, B. subtills, B. cereus, C. perfringens, K. pneumoniae, L. lactis, M. smegmatis, S. marcescens, S. pyogenes, A. viridans, E. aerogenes, S. liquefaciens, P. vulgaris, S. enteridis, P. mirabills, S. abaetetuba, L. monocytogenes, N. Gonorrhoeae, Legionella, M. Gordanoae and M. catarrhalis and viruses including coronavirus, rotavirus, adenovirus, herpes simplex, papillovirus, rhinovirus, hepatitis B and A, enterovirus and parainfluenza virus.
- Bacterial infections and protozoal infections, and disorders related to such infections, which may be treated or prevented in animals, birds, fish and insects, include the following: bovine respiratory disease related to infection by P. haemolytica, P. multocida, Mycoplasma bovis, or Bordetella spp.; cow enteric disease related to infection by E. coli or protozoa (i.e., coccidia, cryptosporidia, etc.); dairy cow mastitis related to infection by S. aureus, Strep. uberis, Streptococcus agalactiae, Streptococcus dysgalactiae, Corynebacterdum, or Enterococcus spp.; swine respiratory disease related to infection by A. pleuro., P. multocida, or Mycoplasma spp.; swine enteric disease related to infection by E. coli, Lawsonia infracellularis, Salmonella, or Serpulina hyodysinteriae; cow footrot related to infection by Fusobacterium spp.; cow metritis related to infection by E coli; cow hairy warts related to infection by Fusobacterium necrophorum or Bacteroides nodosus; cow pink-eye related to infection by Moraxella bovis; cow premature abortion related to infection by protozoa (i.e. neosporium); urinary tract infection in dogs and cats related to infection by E. coli; skin and soft tissue infections in dogs and cats related to infection by S. epidermidis, S. intermedius, coagulase neg. Staphylococcus or P. multocida; and dental or mouth infections in dogs and cats related to infection by Alcaligenes spp., Bacteroides spp., Clostridium spp., Enterobacter spp., Eubacterium, Peptostreptococcus, Porphyromonas, or Prevotella, American and European foul brood in bees caused by Bacillus larvae and Melissococcus pluton, chalkbrood in bees, a fungal disease associated with Ascophera apis and Nosema in bees caused by a protozoan Nosema apisl; bacterial kidney disease (BKD) in salmon, Enteric Redmouth Disease (ERM) of salmon as caused by the bacterial pathogen Yersinia ruckeri, and, Vibriosis a bacterial disease of salt-water and migratory fish caused by the bacterium Vibrio anguillarum or Vibrio salmonicida, known as a cold water vibriosis which affects Atlantic salmon.
- Viral infections and disorders associated with such infections which may be treated or prevented in animals and birds include the following: bovine herpesvirus 1-5 (BHV), ovine herpesvirus 1 and 2, Canine herpesvirus 1, equine herpesvirus 1-8 (EHV), feline herpesvirus 1 (FHV), and pseudorabies virus (PRV), porcine herpesvirus (PRV) or Aujeszky's disease (pseudorabies virus or PRV), the porcine reproductive respiratory syndrome virus (or PRRSV), the swine influenza virus (SIV), the conventional hog cholera virus (or HCV), parvoviruses in porcines, bovine respiratory syncitial virus (BRSV), bovine diarrhoea virus (BVDV), porcine reproductive respiratory syndrome virus (PRRSV), swine influenza virus (SIV), rabies virus, hog cholera virus, porcine parvoviruses (HCV), herpesvirus of turkeys (HVT), Infectious Bovine Rhinotracheitis (IBR), Avian Infectious Bronchitis Virus (IBV), Avian Influenza Virus, Fowlpox-Virus, Avian Infectious Laryngotracheitis Virus (AILV), Mycoplasma Marek's Disease Virus (MDV), Newcastle Disease Virus (NDV), Avian Paramyxovirus Type 1, Avipoxvirus Isolates such as Juncopox, Pigeon Pox, and Field—(Field) and vaccine strains of bird pox viruses, Avian Encephalomyelitis Virus, Avian Sarcoma Virus, Rotavirus, Avian Reovirus and H7 Influenza Virus.
- The present invention also relates to a method of controlling a pest infestation in an animal, bird, fish or insect. Pests which may be controlled include ecto and endoparasites. Examples of pests which may be controlled by the method of the present invention include gastrointestinal worms such as liver fluke, hookworm, heartworm whipworm and tapeworm; ticks, mites, lice and flies.
- The composition may be in any suitable form and for internal or external use. Preparations for internal use include powders, tablets, dispersible granules capsules, solutions, suspensions, and emulsions suitable for oral ingestion or injection. In a preferred embodiment, the composition is provided in the form of a food supplement which may be added to an animal's food or water supply.
- The composition may also find use as a topical anti-microbial and/or anti-parasitic agent. Examples of such applications include antiseptic scrubs or washes and flea and lice shampoos, spray, plunge dips and pur-on formulations.
- The topical compositions may also be administered in the form of wound dressings, transdermal patches and the like. Typically, although not exclusively, wound dressings are impregnated with a composition of the invention at a concentration of active agents of between about 10000 to about 5000 ppm.
- In a further application, the composition may be applied in the form of an aerosol. Such formulations may be used for the treatment of lung infections.
- In preferred embodiments, without limitation to only those disclosed herein and without disclaimer of other embodiments, effective dosing may be determined in accordance with the disease and the level of infection encountered. As some examples only, and without limitation, if the disease is detected early in the infection, one may use doses of between 5-10 mg per kilo body weight. If the disease is detected when the infection has taken a strong hold, one may use between 50-100 mg per kilo body weight. As a prophylactic dose to prevent disease, i.e. influenza, one may use dose levels of 1-5 mg per kilo body weight.
- In the methods of the invention, the composition may also be applied to the locus of an animal, fish, bird or fish. Where the composition is used to treat infections and infestation in fish the composition may also be in the form of an additive which may be added to the water in a fish or holding tank.
- The composition may also be used in the form of a fumigant for the purposes of controlling infectious agents in an animal enclosure such as a dairy, stable, pen or the like. A particular application is the fumigation or fogging of bee hives to control or treat mite infestations.
- Without limiting embodiments of the invention to only those expressly disclosed herein and without disclaiming other embodiments, Table 2 describes further treatment details and methods that comprise some embodiments of the invention. For purposes herein, including without limitation, for Table 2 and the examples below, “base composition” means the composition of Example 3 below or reasonable equivalents thereof.
- The following examples are provided without limiting the invention to only those embodiments described herein and without disclaiming other embodiments.
- Without limitation to any particular process, a basic process for manufacture of Melaleuca alternifolia essential oil is as follows:
- The plants are harvested from a field by cutting the scrubs off just above ground level. They are mulched and placed into a steel trailer-like transport vessel. The trailer is brought into a distillation shed. Steam is pushed through the mulched wood and leaf mix, and water and oil is collected via a stainless steel condenser. The oil is centrifuged out of the water oil mix and collected. The oil is then cleaned up and concentrated for the final product.
- In some embodiments, without limitation to only those embodiments expressly disclosed herein, essential oil from Melaleuca alternifolia oil has the following characteristics:
- Product Name: Oil of Melaleuca alternifolia
- Synonyms: Tea Tree Oil; Melaleuca Oil; Oil of Melaleuca, Terpinen-4ol type
- Definition. Essential oil steam distilled from the leaves and terminal branchlets of Melaieuca alternifolia
- Chemical Abstract No.: 68647-73-4
- UN No.: 2319
- Tariff CN Code: 3301.29.61
Physical Properties: - Appearance: Clear, mobile liquid with no visible trace of water
- Color: Colorless to pale yellow
- Odor: Characteristic warm, spicy odor
- Specific Gravity@20 degreesC/20 degrees C: 0.885-0.906
- Refractive Index@20 degrees C: +5o to +15o
- Solubility@20 degrees C: 1 vol soluble in 2 vols 85% v/v ethanol
- Chemical Properties:
Analysis: 1,8 Cineole 3% +/.1% Terpinen-4-ol 39% +/.2% - Typical analysis by gas chromatography
Constituent Proportion ISO Standard alpha-pinene 2.4% 1-6% sabinene 0.6% trace-3.5% alpha-terpinene 10.2% 5-13% p-cymene 2.2% 0.5-12% Limonene 1.1% 0.5-4% 1,8-cineole 3.6% 0-15% gamma-terpinene 20.5% 10-28% alpha-terpinolene 3.6% 1.5-5.0% terpinene-4-ol 40.2% 30%+ alpha-terpineol 3.1% 1.5-8% aromadendrene 1.1% trace-7% delta-cadinene 1.0% trace-8% globulol 0.3% trace-3% viridiflorol 0.3% trace-1.5% - Without limitation, some embodiments of the invention comprise a composition prepared by removing essentially all the monoterpene fraction from Melaleuca altemifola essential oil. The composition of said oil after removal of the monoterpene fraction is about as follows:
- Test Results
Weight Compound PerCent* CAS No. Para cymene 0.34 000535-77-3 Alph Terpinene 1.15 000099-85-4 Linalool 0.37 029050-33-7 2-cycohexen-1-ol,1-methyl- 0.27 029803-82-5 4-1(1-methyethyl)-,cis 2/cyclohexen-1-ol,1-methyl-4- 0.68 029803-81-4 91-methylethyl 2-cylohexan-1-ol,methyl- 0.53 029803-82-5 4-(1-methylethyl)-cis Terpinene-4-ol 48.90 000562-74-3 Alpha terpineol 9.04 000098-55-5 2-cyclohexen-1-ol,3-methyl- 0.49 016721-38-3 6-(1-m-ethylethyl)-cis Cyclohexanol,2,3,5- 0.41 000116-02-9 trimethyl 2,4-heptadiene,2,6-dimethyl- 0.42 004634-87-1 Sorbic acid 0.39 000110-44-1 Viriflorol 0.37 1000156-10-8 Cubebene 0.64 017699-14-8 Isoeugenyl methyl ether 0.26 000093-16-3 2-cyclopenten-1-one,3,4,5- 0.19 055683-21-1 Trimethyl Beta caryophyelline trans 1.11 000489-40-7 Caryophyllene 1.08 000087-44-5 1h-cyclopropa(a)naphthalene 0.28 020071-49-2 alloaromadendrene 4.39 025246-27-9 111-cycloprop(e)azulene 1.01 126362-40-7 1a,2,3,4,ra,5,6,7b-octahydro-1,4,7 tetrame Alpha Carophyllene 0.43 006753-98-6 Aromadendrene 1.71 000489-39-4 Isolendene 1.31 1000156-10-8 Naphthalene,1,2,3,4,4a,5,6,8a- 0.97 005951-61-1 Hexahyd Gama Gurguene 4.04 021747-46-6 Azulene,1,2,3,4,5,6,7,8-octahydro- 2.79 000088-84-6 1,4-dimethyl-7-(1-methylethylidene) Alpha thugene 4.72 000483-76-1 Naphthalene,1,2,3,4-tetrahydro-1 2.13 000483-77-2 6-dimethyl-4-(1-methylethyl) Alpha cubenbene 0.77 017699-14-8 Lipiglobulol 0.66 100150-05-1 Tricyclo(6.3.0.1)undec-7-ene 0.40 1000152-25-6 6,10,11,11-tetramethyl Spathulenol 0.96 077171-55-2 Globulol 1.47 1000150-05-0 III-cycloprop9c)azulen-4-ol 1.40 000552-02-3 IH Indene, 0.78 056324-68-6 1-ethylideneoctahydro-7 Naphthalene,1,2,3,4,4a,7-hexahydro- 1.49 016728-99-7 1,6-dimethyl-4-(1-methylethyl Viridflorene 0.92 058569-25-8 Copaene 0.73 003856-25-5
*General analysis as determined by Gas Liquid Chromatography Mass Spectrophotometer analysis. Those of ordinary skill in the art will appreciate that such determinations may vary between or among test machines and conditions based on factors which include, but are not limited to, column material, temperature of injection port, oven temperature, and/or detection system. Thus, the formulation above is exemplary without limiting
# the embodiments to only those listed and without disclaiming other embodiments not specifically listed herein.
Physical Properties: - Color—Pale Yellow
- Aroma—Medicinal
- Clarity—Clear
- Viscosity—1.080
- Specific Gravity—0.943
- Boiling point—approx. 148 degrees C
- Density by weight—0.9259
- Use of the base composition was tested in conjunction with the control of avian H5N1 virus.
- One day old chicks were supplied a water soluble solution of the base composition at a 10% concentration level. This was a stock solution which was broken down with water to 200 ppm or 0.02%. The diluted solution was fed to the chickens from day one until 48 hours prior to slaughter and dressing. Findings indicated that the body weight will increase from traditional feeding systems; as a consequence, time of housing to kill may decrease and that will depend upon target finish weight, i.e., in Australia they aim for 3.2 kilos average live chicken.
- For already growing chickens, a fogging system was developed to protect the birds from the virus before the change over to new 1 day old birds.
- The fogger delivered about 10 to 30 micron droplets of 1% base composition solution, with about 2 liters per 25,000 birds per spray. All parts of the animal storage shed were sprayed as well as the birds so that they inhale the test solution into their systems, so offering not only a virus free environment but also the base composition transferred into the blood system via the lungs of the growing birds. The sheds and litter were fogged prior to the birds being placed in the sheds or in the case of established sheds, the birds are fogged daily for the first week and then weekly.
- A protocol for chicken treatment to prevent avian H5N1 virus infection was established. Other trials have shown that concentrations of birds deliberately infected with a range of levels of virus produce results from death to sick birds, to no reaction to the virus introduction.
- The virus H5N1 was grown in fertile eggs titer established and then by serial dilution made into the following concentrations of virus:
-
- 1. 10×6
- 2. 10×5
- 3. 10×4
- 4. 10×3
- 5. 10×2
- In the cases of birds infected at 1 and 2 all were dead in 36 hours.
- In the case of level 3, one bird died in 36 hours; two birds were found dead on day 4; one bird found dead on day 6, and one bird survived for 11 days but was terminated although it may have recovered.
- In both cases 4 and 5, the birds showed no signs of clinical distress.
- In case 3 antibodies were detected while in cases 4 and 5 no antibodies were found.
- The study indicated that the birds infected to levels of 10×4 plus had virus take hold and kill the birds but at varying rates.
- The fact that no antibodies were located in cases 4 and 5, i.e., 1000×100 cells per ml ingestion levels suggested that the virus could not establish a growth rate sufficiently to cause infection or death in the birds.
- From live bird trials, we have established that feeding chicks from day one at a level of 200 ppm of the base composition in their water bred health chickens. The studies also showed that both male and female birds reached a body weight at 56 days of about 4.3 kilograms, high for normal birds and occurring in both sexes. Although these birds were not exposed to the avian virus it does show a high rate of food conversion to body weight donating healthy birds.
- This further indicates that if the viral infection of the birds is low to begin with, around 10×4 that daily uptake of the base solution in the drinking water may stop or depress the growth rate of the virus, allowing the birds to survive, and produce antibodies to further attack and kill the virus if they do become infected.
- Combining a fogging system at 1% base composition in the sheds to kill or reduce virus and other bacteria (e.g., S. aureus, E. Coli, etc.) should contain all infections both viral and bacterial and without the use of antibodies. This would have the added advantage of speeding up the growth time of the birds, and improve the turn round time in the sheds, with cost-effective reduction in feed, use and housing time, and the like.
- The antimicrobial activity of a composition comprising some embodiments of the invention was examined. The base composition was tested using a 96-well microtiter tray and the concentrations of the base composition were in the range of about 2-0.0025%.
- Food pathogens were prepared in double-strength Mueller Hinton broth, resulting in the organisms at final concentrations between 1.5×105-2.5×106 cfu/ml. Tests were incubated at 35° C. for 24 hours and subcultured by removing 10 microliters from tray wells and spot inoculating onto blood agar. All subcultures were incubated and the colonies counted. The minimum inhibitory concentration (“MIC”) was defined as the lowest concentration of product resulting in the maintenance or reduction of the inoculum. The minimum cidal concentration (“MCC”) was defined as the lowest concentration of product resulting in the death of 99.9% of the inoculum. The tests were carried out twice. If discrepant results were obtained, a third test was conducted.
- The MlCs of strains of Campylobacter jejuni were determined by agar dilution using Mueller Hinton Agar containing 5% lysed horse blood. The inocula were prepared in 0.85% saline and a volume of 10 ul/spot was applied onto the MHA plates. The final concentration was approximately 5×105×1 Os cfu/spot. All results were read after 48 h of incubation in a 37° C. in a microaerophilic atmosphere (5% 02, 10% CO2, 85% N2). The MIC was defined as the lowest giving complete inhibition of visible growth. See Table 3 below for results.
- A composition comprising some embodiments of the invention was tested, starting at 10% base concentration, against 20 clinical isolates.
- Testing on Vancomycin resistant Enterococcus faecium and faecalis (“VRE”) bacteria as well as MRSA, major problem in some medical facilities.
- We found that golden staph bacteria were inhibited at 0.12% base composition; VRE bacteria were inhibited at 1% concentration of base composition; and ESBL bacteria were inhibited at 0.5% concentration of base composition.
- One embodiment was tested against 20 clinical isolates of multi-resistant methicillin resistant Staphylococcus aureus using agar dilution techniques. The tested concentrations initially were 0.03% and 0.06% base composition. All 24 clinical strains including ATCC controls grew at both concentrations, Agar dilution testing was repeated using additional concentrations ranging from 0.015% to 2% base composition. Secondary testing was performed.
- Complete inhibition of all clinical and control samples was detected at a concentration of 0.25% v/v base composition. 58% (14/24) of the clinical strains were inhibited at a concentration of 0.12% v/v base composition. All clinical isolates and ATCC control strains of Staphylococcus aureus were inhibited than a concentration of 0.25% v/v.
- A 10% solution of the base composition was tested against 20 clinical isolates of the vancomycin resistant Enterococcus species using an agar dilution technique.
- 13 vancomycin resistant strains of Enterococcus faecium and seven vancomycin resistant strains of Enterococcus faecalis were tested. Organisms were selected from a time period spanning five years to minimize the potential for testing of clonal isolates. 14 strains exhibiting the vanB genotype (high level to vancomycin resistance plus teicoplanin susceptibility) were tested compared to six strains with the vanA genotype (high level vancomycin and teicoplanin resistance). This distribution reflects the predominance of the vanB Enterococcus faecium in nosocomial outbreaks in Australia.
- Our studies found complete inhibition of all clinical and control strains of Enterococcus species at a concentration of 1% v/v. All clinical excellence and ATCC control strains of vancomycin resistant Enterococcus were inhibited at a concentration of 1% v/v irrespective of resistance genotyping species.
- Mycobacterium avium subspecies paratuberculosis (M. paratuberculosis) is a very slow growing mycobactin dependent mycobacterial species known to be the causative agent of Johne's disease (paratuberculosis) in all species of domestic ruminants. The bacteriostatic activity (growth inhibition) of the base composition was tested on following mycobacteria:
- M. paratuberculosis (strains CLIJ62, CLIJ748, ATTCJ9698)—slow growing mycobacterial species with lengthy growth period in vitro on solid based laboratory media and a more rapid growth cycle in a selective broth environment;
- M. avium (strain D4)—a moderate growing mycobacterial species; and
-
- M. smegmatis (strain mc2155)—a fast growing non-pathogenic mycobacterium
- The BACTEC™ 460 radiometric system is a well established semi-automated broth-based culture system procedure that provides rapid detection of M. paratuberculosis. The BACTEC procedure for antimicrobial susceptibility testing of mycobacteria is based on the same basic principal used in the conventional method: for bacterial propagation a liquid medium is used instead of counting colonies after a long incubation period, the growth is monitored radiometrically, and results are reportable within a shorter time frame. The amount of 14CO2 released from 14C-labelled substrate reflects the rate and amount of growth occurring in the vial and is expressed in terms of the “Growth Index” (“GI”). Bacteria were considered:
- Susceptible: when GI was completely abolished during the course of experiment;
- Inhibited: when GI was partially (temporarily) inhibited during the course of experiment;
- Resistant: when was not affected during the course of experiment.
- The bacteriostatic activity (“growth inhibitions) of the base composition for mycobacteria in the active phase of growth was evaluated in vitro using the BACTEC 460 radiometric culture system using three concentrations of base composition solution supplied. The MICs determined for M. paraetuberculosis, M. avium and M. smegmatis were 0.1%; 0 125%r and 0.15% base composition. Growth inhibition was dependent on the inoculum size, source, growth rate and incubation period. We concluded that:
- the base composition is able to affect the bacterial metabolism of all three mycobacteria species tested at concentrations low as 1% of the 10% base composition solution;
- M. paratuberculosis appeared most susceptible to the base composition;
- unrestricted growth of each bacterial inoculum was observed in all culture vials in the absence of antimicrobial agent or diluent (vitamin E solution);
- acid fastness detected by Ziehl Neelsen staining of the mycobacterial suspensions confirmed the purity of all cultures and the presence or absence of mycobacteria; and
- growth inhibition depends on the activity of the inoculum, the rate of growth and the incubation period.
- The acute oral toxicity of the base composition was investigated in 4 Sprague Dawley Specific Pathogen Free (“SPF”) rats at doses of 500 and 1000 ppm base composition at 10 mL/kg. The experimental procedure was based on OECD guidelines for the testing of chemicals No. 401.
- The test solution was administered orally once to 2 pairs of rats at the above doses. A third group was administered the vehicle only, solubilized vitamin E solution. The equivalent volumetric dose was 10 ml/kg for all groups.
- Body weights were determined immediately before test item administration and at sacrifice on day 8. All animals were observed at frequent intervals on the day of test item administration and then daily for signs of toxicity over the 7 day experimental period, at the end of the experimental period, all animals were sacrificed and subjected to a gross necroscopy examination.
- Results showed that no mortalities were observed during the study; no clinical abnormalities were observed for the duration of the study in any of the treated or control animals; and there were no gross abnormalities noted in the major organs of any animal at necroscopy. Further analysis was carried out by gas chromatography testing of the kidneys and livers. No traces of the components of the base composition were found, indicating that all compounds are successfully excreted from the body.
- Based on the results obtained from this study, the base composition, up to the highest doses tested 1000 ppm at 10 ml/kg, did not produce toxicity in the Sprague Dawley rat. These results may be compared to tea tree oil which has been reported to have an LD50 of 1.9-2.6 ml/kg.
- Acute oral toxicity testing in rats revealed no signs of toxicity at tested levels.
- In one study, the acute oral toxicity of 10% solution of base composition was investigated in groups of 2 Sprague Dawley Specific Pathogen Free (SPF) rats at a single dose level. The test solution was administered orally by intragastric gavage to one (1) group of 2 rats (1/sex) at the maximum administrable volume of 10 mL/kg. A control group of 2 rats (1/sex) was dosed with the vehicle alone (water). Body weights were determined immediately before test item administration and daily thereafter. All animals were observed at frequent intervals on the day of test item administration, and then daily for signs of toxicity over the 7-day experimental period. At the end of the experimental period, on Day 8, all surviving animals were sacrificed and subjected to a gross necropsy examination. There were no deaths or abnormal clinical signs in any animal during the experimental period. Overall body weight gains occurred in all animals. There were no gross abnormalities found in the major organs of any animal treated with the vehicle or test item at autopsy. Under the conditions of this study, the tested 10% solution produced no signs of toxicity when administered at a volume of 1 mL/kg.
- Dermal toxicity studies in guinea pigs revealed no signs of toxicity at tested levels.
- Thirty Duncan-Hartley Guinea Pigs (25 females and 5 males) were ranked by weight and sex and then randomly allocated into five groups of females (n=5 per group) and one group of males (n=5). The treatment groups met the regulatory requirements of having the No Observable Effects Limit (“NOEL”) group, the Lowest Observable Effects Limit (“LOEL”) group, and the Mean Dose Lethality (MDL) or Maximum Toxicity Dose (“MTD”) group.
- On Day 0 of the study, Groups 1 (NOEL) and 3 (MTD/MDL) were treated with a 5%, 15%, and 25% formulation of base composition. Group 4 received treatment with 100% base composition and served as an extreme positive control. Group 5 received the vehicle, consisting of a specifically formulated Vitamin E base and served as a primary negative control. Treatment was administered via a treated gauze pad containing 2 ml of the test substance applied directly to a 2 cm square shaved are on the dorsum of each guinea pig. This provided a direct application of 1 ml/cm2. The five male guinea pigs were additional to Group 3 and met the requirement of having on test a group of alternate sex subjects receiving the MTD/MDL dose.
- Health scores were documented for each individual guinea pig twice daily. Observations were more frequent on the day of treatment. Particular attention was paid to immunogenic, vasodilatory or necrotizing changes of the treatment area. Post mortem examinations were performed on all animals at the end of the study, as none had died on test and any gross abnormalities were documented on a Necropsy Record. Histological examination was conducted on skin tissues taken from the treatment area from each group. Had any gross abnormalities been observed on necropsy, these tissues would have been submitted for histopathological examination. There were no abnormalities identified and therefore this procedure was not performed.
- Abnormal findings occurred in those animals on test designated as Group 4 or also identified as the positive control group. It was anticipated that necrotizing changes would occur within this group. None of the animals in the test dose groups had been affected and therefore it was determined that there was no toxic effect when administered cutaneously to guinea pigs at the 5%, 15% and 25% levels as an acute study for toxicity. Gross pathology, and health scores were basically normal for the animals on test. Only those animals in the positive control group demonstrated any abnormal findings as was anticipated. There was no evidence of an induced response between those animals receiving the test substances and those receiving the negative control substance resulting in an identifiable or measurable difference of any significance. Weight gain analysis demonstrated a strong equivalence amongst all groups over the duration of the test including the positive control group suggesting that any adverse changes were local and not systemic in nature. The overall finding of the study was that the base composition, when administered as a single bolus to guinea pigs on an acute toxicity test by dermal application, did not demonstrate any increasing toxic effect corresponding to dosage.
- The effect of the base composition on microbial infections was tested in vitro. In microbiological testing, plates were prepared using Tryptic Soy Agar (bacteria) and Malt Extract (yeast and mould).
- All microorganisms were tested against 108 (MacFarland Standard) concentration of micro organism, etc. The MacFarland turbidity standard system was used to estimate the level of bacteria in a solution by the opacity of the liquid against a known MacFarland tube purchased from a biological supplier
- The results are shown in the following Table:
No pf tests Average zone of carried inhibition/mm E. Coli 105 24 S. aureus 68 30 P. aeruginosa 48 22 C albicans 60 35 S epidermidis 30 38 Penicillium ssp 68 Ng Cladosporium 89 Ng A. Niger 65 Ng A. fumigatus 5 Ng P. Expansum 5 Ng S. chartarum 4 Ng Alternaria 10 Ng Aspergillus 5 Ng Fusarium 4 Ng B. subtilise 15 35 B. cereus 20 35 C. perfringens 5 Ng K. pneumoniae 2 Ng L. lactis 1 Ng M. Smegmatis 5 Ng S. Macescens 3 Ng S. pyogenes 3 Ng A. viridans 10 Ng E. aerogenes 2 Ng S. liquefaciens 2 Ng P. vulgaris 15 Ng S. enteridis 4 Ng P. mirabilis 5 Ng S. abaetetuba 15 Ng L. monocytogenes 20 Ng N. Gonorrhoeae 5 Ng Legionella 10 35 M. Gordanoae 14 35 M. catarrhalis 3 Ng
ng denotes no growth
- The efficacy of the base composition in inactivating H5N1 virus in an egg test environment was tested. Work was done to confirm the ability of the base composition to act as a virucidal agent against a Vietnamese H5N1 highly pathogenic avian influenza virus strain.
- A 10% solution of the base composition (Batch 020405) was made in dimethyl sulphoxide (DMSO) by adding 1.0 ml of base composition to 9.0 ml of DMSO and mixing thoroughly. A solution of 1% base composition with no emulsifiers (Batch 102034) was supplied (NeuMedix Ltd, Underwood, Queensland, Australia) and used as supplied for virus treatment.
- The virus was A/chicken/Vietnam/8/2004 H5N1 grown in the allantoic sac of embryonated, SPF chicken eggs. Infectious allantoic fluid was harvested, pooled and stored at −80° C. for this trial. The microstores pool reference number of this material is 0404-30-1550.
- The 10% base composition was diluted 1:5, 1.3.3 and 1:2.5 in phosphate buffered saline (pH 7.3) to give final concentrations of 2%, 3% and 4% respectively. Based on ASTM E1052-96, 0.1 ml of virus was mixed with 0.4 ml of base composition at concentrations of 2%, 3% and 4%. Mock-treated virus, consisting of 0.1 ml of virus mixed with 0.4 ml of a 1:5 dilution of DMSO without added base composition in PBS and untreated virus, consisting of 0.1 ml of virus mixed with 0.4 ml of PBS, were also prepared. All mixtures were incubated at room temperature for the respective times. 2%, 3% and 4% base composition solutions were diluted 1:10 in PBS and 0.1 ml inoculated into 5 eggs each.
- Virus Titrations
- Trial 2—in SPF Eggs
- Residual virus was assayed by making 10-fold dilutions in PBS of each virus mixture from 10−1 to 10−80.02 ml of virus mixture was added to 1.8 ml of PBS and mixed thoroughly to give a 10−1 dilution. 0.2 ml of this was added to 1.8 ml of PBS and mixed thoroughly to give a 10−2 dilution and so on to a final dilution of 10−80.01 ml of each dilution was inoculated into the allantoic sac of embryonated, SPF chicken eggs, incubated at 37° C. for 3 days or until embryo death. Eggs were examined twice daily for viability. At death or after 3 days incubation all eggs were chilled overnight at 4° C. and then tested for the presence of hemagglutination and an indicator of virus infection. The residual infectivity tire was calculated by the method of Reed, and Meunch.
- Results
- The base composition treatments and egg inoculations for this trial showed no egg mortalities due to the effects of the virus inoculum.
- Summary of Titration Results of Trial 3:
- Log 10 residual virus titer after base composition treatment in (EID50/0.1 ml)
Base composition Treatment Time concentration 60 Minutes 120 Minutes 240 Minutes 2% 4.1 4.5 3.1 3% 2.9 3.5 2.9 4% 3.1 2.7 0 Untreated virus 7.1 Mock-treated virus 7.5 - From the results presented above, we concluded that the base composition can inactivate between 0.3 and 7.1 log 10 of H5N1 avian influenza virus depending on the base composition concentration and contact time between the virus and base composition. A 7.1 log 10 inactivation means that all virus was killed. Eggs inoculated with base composition solutions alone showed no egg deaths.
- Analysis by electron microscopy was conducted to evaluate changes in the ultrastructure of the virus after administration of the composition.
- A solution of base composition in phosphate buffered saline (pH 7.3) to give a final concentration of 4%. Mock-treated virus, consisting of 0.1 ml of virus mixed with 0.4 ml of a 1:5 dilution of DMSO without added base composition in PBS and untreated virus, consisting of 0.1 ml of virus mixed with 0.4 ml of PBS, were also prepared. All mixtures were incubated (three hours, 180 mins) at room temperature for the respective times. Concentrations and times were selected in accordance with experience from previous experiments. The parameters were selected as they resulted in significant reduction in virus titer:
TABLE 4 Treatment Time Test concentration 60 Minutes 120 Minutes 240 Minutes 2% 4.1 4.5 3.1 3% 2.9 3.5 2.9 4% 3.1 2.7 0 Untreated virus 7.1 Mock-treated virus 7.5
Log 10 residual virus titer after base composition treatment in (EID50/0.1 ml) - Solutions were prepared for negative contrast electron microscopy as per the protocol described in the QA manual. All samples were imaged with a Philips CM 120 at 100 kK and recorded with a MegaView III digital camera.
- Upon treatment of H5N1 virus with 4% base composition for three hours, the ultrastructure of the virus changes. Positive control samples displayed ultrastructure consistent with that described for viruses belonging to the family Orthomyxoviridae (Virus Taxonomy. Eight Report of the International Committee on Taxonomy of Viruses. Edited by C. M. Fauqet, M. A. Mayo, J. Maniloff, U. Desselberger, L.a. Bail. Elsevier, Academic Press, 2005, pgs. 681-693). The ultrastructure of H5N1 treated as described differed in that the stain penetrated the membrane envelope and the majority of surface projections were absent. The ability of the stain to penetrate a greater proportion (subjective observation) of viruses following treatment may be indicative of disruption to the envelope.
- To gain an appreciation of the significance of the above changes it should be noted that the surface membrane incorporates various viral proteins and support the surface projections (which are required for infection of host cells) whilst encompassing the viral nucleic acid (nucleocapsid) which is required for replication. One interpretation of the ultrastructural changes could be the inference that they are consistent with the data in Table 4 which show a substantial rise in viral inactivation when H5N1 is exposed to a 4% concentration of base concentration for a contact time of greater than 120 mins.
- Bees
- Varroa Mites
- Trial 1
- Extensive field trials have been conducted on 2500 bee hives. The level of mite infection was estimated by catching individual bees and counting the number of mites thereon. Without any treatment at all, the average number of mites per 50 bees was 10.
- About 70 to about 90 grams of the base composition at a concentration of 1000 ppm in food grade mineral oil as a carrier was fogged into each hive. Fogging was conducted initially for three consecutive days and then every 10 days all year round.
- Treatment with the inventive composition reduced the mite infestation level to about 1 mite per 50 bees.
- Comparative trials were conducted with food grade mineral oil on its own and also mixtures of eucalyptus, lavender, and commercially available tea tree oil with food grade mineral oil under the conditions recited above. The level of mite infestation after these comparative treatments was about 5 mites per 50 bees.
- It may be seen that these field trial results indicate that the composition of the present invention is superior to current methods of varroa mite control in bee hives.
- Trial 2
- In the light of the positive field trial results, a further controlled trial is to be conducted as outlined below:
- A honey bee colony will be selected with at least 50 varroa mites per 300 bees. Approximately 300 bees will be placed in each of 30 metal cages (105×100×40 mm with mesh on one side and glass on the other. Honey will be provided on the floor of the cage on an upturned lid. Additional food will be provided in the form of 2M sugar syrup.
- Ten cages of bees will not be treated as negative controls. The base composition will be mixed with food grade mineral oil at 500 and 1000 ppm. This will then be applied to the bees through the mesh on the cage using a fogger. Each treatment and rate will be replicated ten times. The actual application amount will be calculated by weighing the cages before and after fogging.
- After fogging, the number of mites to fall to the bottom of the cages will be counted after 4, 24 and 48 hours. After 48 hours, the bees w ill be removed, counted and washed in alcohol to remove any live mites.
- European Foulbrood
- European foul brood (EFB) is a disease of honey bee larvae caused by Melissococus pluton, a gram positive bacteria. EFB kills larvae at about 3 days of age but doe not affect adult bees. From the results given above under the heading Microbiological testing, it would be expected that a base composition would be effective in the control of EFB.
- It is proposed to determine the minimum inhibitory concentration of the base composition of Example 3 to M. pluton. When this concentration has been determined, trials will be conducted with infected bee colonies to illustrate the effectiveness of the composition of Example 3 against EFB.
- All attachments, tables, and cited references are hereby incorporated by reference in their entireties as though fully set forth herein.
- It will be appreciated that various changes or modifications may be made to the invention as described and claimed herein without departing from the spirit and scope thereof. While the present invention has been particularly shown and described with reference to the foregoing preferred and alternative embodiments, it should be understood by those skilled in the art that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention without departing from the spirit and scope of the invention as defined in the following claims. It is intended that the following claims define the scope of the invention and that the method and apparatus within the scope of these claims and their equivalents be covered thereby. This description of the invention should be understood to include all novel and non-obvious combinations of elements described herein, and claims may be presented in this or a later application to any novel and non-obvious combination of these elements The foregoing embodiments are illustrative, and no single feature or element is essential to all possible combinations that may be claimed in this or a later application. Where the claims recite “a” or “a first” element of the equivalent thereof, such claims should be understood to include incorporation of one or more such elements, neither requiring nor excluding two or more such elements.
TABLE 1 Plants of the Myrtaceae Family Acmena smithii (Lilly-Pilly Tree) Agonis flexuosa (Peppermint Tree, Australian Willow Myrtle) Agonis juniperina (Juniper Myrtle) Angophora costata (Sydney Red Gum, Smooth-Barked Apple) Astartea fascicularis Baeckea virgata Callistemon citrinus (Lemon Bottlebrush, Crimson Bottlebrush) Callistemon linearis (Narrow-leafed Bottlebrush) Callistemon rigidus (Stiff Bottlebrush) Callistemon salignus (White Bottlebrush) Callistemon viminalis (Weeping Bottlebrush) Callistemon viminalis ‘Little John’ (Callistemon ‘Little John’, Dwarf Bottlebrush) Calothamnus quadrifidus Calothamnus villosus (Silky Net Bush, Woolly Net Bush) Calytrix tetragona (Fringe Myrtle) Chamelaucium uncinatum (Geraldton Waxflower) Eucalyptus albens (White Box) Eucalyptus caesia (Gungurru) Eucalyptus camaldulensis ssp. camaldulensis (River Red Gum) Eucalyptus camaldulensis ssp. obtusa (Murray River Red Gum, Red Gum) Eucalyptus campaspe (Silver Topped Gimlet) Eucalyptus cinerea (Ash-Colored Eucalyptus) Eucalyptus citriodora (Lemon Scented Gum) Eucalyptus cladocalyx (Sugar Gum) Eucalyptus conferruminata (Bushy Yate) Eucalyptus cornuta (Yate) Eucalyptus deglupta (Mindanao Gum) Eucalyptus eremophila (Tall Sand Mallee, Horned Mallee) Eucalyptus erythrocorys (Red Cap Gum, Illyarrie, Bookara Gum) Eucalyptus erythronema (Red-flowered Mallee) Eucalyptus ficifolia (Red Flowering Gum, Scarlet Gum) Eucalyptus formanii (Forman's Mallee) Eucalyptus globulus (Tasmanian Blue Gum) Eucalyptus gracilis (Yorrell) Eucalyptus grossa (Coarse-flowered Mallee) Eucalyptus gunnii (Cider Gum) Eucalyptus incrassata (Lerp Mallee) Eucalyptus kruseana (Kruse's Mallee) Eucalyptus largiflorens (Black Box) Eucalyptus leucoxylon (White Iron Bark) Eucalyptus macrocarpa (Mottlecah) Eucalyptus maculata (Spotted Gum, Spotted Iron Gum) Eucalyptus mannifera ssp. maculosa (Red-spotted Gum) Eucalyptus megacornuta (Warted Yate) Eucalyptus melliodora (Yellow Box) Eucalyptus microtheca (Coolibah) Eucalyptus nicholii (Willow Peppermint) Eucalyptus niphophila (Snow Gum) Eucalyptus orbifolia (Round-leafed Mallee) Eucalyptus papuana (Ghost Gum) Eucalyptus pauciflora (Cabbage Gum) Eucalyptus perriniana (Spinning Gum, Round Leaved Snow Gum) Eucalyptus platypus (Round-leafed Moort) Eucalyptus polyanthemos (Silver Dollar Gum) Eucalyptus populnea (Bimble Box, Poplar Box) Eucalyptus preissiana (Bell-fruited Mallee) Eucalyptus pulverulenta (Silver Mountain Gum) Eucalyptus pyriformis (Pear-fruited Mallee) Eucalyptus rhodantha (Rose Mallee) Eucalyptus robusta (Swamp Mahogany) Eucalyptus rudis (Desert Gum, Flooded Gum) Eucalyptus saligna (Sydney Blue Gum) Eucalyptus sargentii (Salt River Mallet) Eucalyptus sideroxylon (Red Ironbark) Eucalyptus spathulata (Narrow Leaf Gimlet, Swamp Mallee) Eucalyptus stellulata (Black Sally) Eucalyptus tetraptera (Square-fruited Mallee) Eucalyptus torelliana (Cadaga) Eucalyptus torquata (Coral Gum) Eucalyptus viminalis (Manna Eucalyptus) Eucalyptus woodwardii (Lemon Flowered Gum, Lemon Flowered Mallee) Eugenia aggregata (Cherry of the Rio Grande) Eugenia apiculata (Palo Colorado) Eugenia brasiliensis (Grumichama) Eugenia jambos (Rose Apple, Pomarrosa) Eugenia luschnathiana (Pitomba) Eugenia uniflora (Surinam Cherry, Pitanga) Feijoa sellowiana (Feijoa, Pineapple Guava) Kunzea baxteri (Scarlet Kunzea) Leptospermum laevigatum (Coastal Tea Tree) Leptospermum petersonii (Lemon Tea Tree) Leptospermum rotundifolium Leptospermum scoparium (New Zealand Tea Tree) Lophostemon confertus (Brisbane Box, Vinegar Tree, Brush Box) Melaleuca alternifolia (Tea Tree, Snow in Summer) Melaleuca armillaris (Drooping Melaleuca, Bracelet Honey Myrtle) Melaleuca decussata (Lilac Melaleuca) Melaleuca diosmifolia (Diosma-Leaved Honey Myrtle, Green Honey Myrtle) Melaleuca elliptica Melaleuca ericifolia (Heath Melaleuca, Swamp Paperbark) Melaleuca hypericifolia (Dotted Melaleuca) Melaleuca incana (Gray Honey Myrtle) Melaleuca linariifolia (Snow-in-Summer, Flax-leaved Paperbark) Melaleuca megacephala Melaleuca nesophila (Showy Honey Myrtle, Pink Melaleuca) Melaleuca quinquenervia (Cajeput Tree) Melaleuca styphelioides (Prickly Paperbark, Prickly-leaved Tea Tree) Melaleuca wilsonii Metrosideros excelsus (Pohutukawa, New Zealand Christmas Tree) Metrosideros karmadecensis (Kermadec pohutukawa) Mosiera ehrenbergii Myrciaria cauliflora (Jaboticaba) Myrtus communis (True Myrtle, Common Myrtle, Roman Myrtle) Myrtus communis ‘Boetica’ (Twisted myrtle) Pimenta dioica (Allspice, Pimento, Jamaica pepper) Pimenta racemosa (West Indian Bay Tree, Bay Rum Tree) Psidium cattleianum (Strawberry Guava) Psidium cattleianum ssp. lucidum (Lemon Guava) Psidium guajava (Tropical Guava) Psidium guineense (Brazilian Guava, Wild Guava) Syzygium aromaticum (Clove) Syzygium francisii (Giant Water Gum) Syzygium paniculatum (Brush Cherry) Syzygium samarangense (Java Apple, Makopa) Tristaniopsis laurina (Kanooka, Water Gum) Ugni molinae (Chilean Guava) - Adapted from http://www.desert-tropicals.com/Plants/Myrtaceae/Myrtaceae.html.
TABLE 2 1. Disease Paratuberculosis Formulation Active Base composition 2.0% Base Carrier Water 97.8% Emulsifier Vitamin E 0.2% Total 100.0% Delivery System Slow dissolving capsule Delivery Load 50 mg per kilo Body weight 2. Disease American Foulbrood Bee Formulation Base composition 1.0% Food Grade Mineral Oil 99% Total 100% Delivery System Fogger Butane type Delivery Load Fog the hive three times to start and then very 10 days 3. Disease European Foul Brood Bees As Above 4. Disease Respiratory infections including the following: Mycoplasma pneumoniae Legionella pneumoniae Streptococcus pneumoniae Haemophlus influenza Chiamydia pneumoniae Formulation Base composition 0.1% Base carrier Canola oil 99.9% Delivery System Liquid Canola Oil Delivery Load 1 ml per kilo/body weight 5. Disease Blood and tissue Infections including the following: Endocarditis, S. auerus, S hamolyticus, E fascalis Osteomyelitis, E durans, beta-lactams vancomycin. Formulation Base composition 0.10% Base carrier saline water 99.89 Vitamin E 0.01% Delivery System Intravenous Injection Delivery Load 1 ml per kilo body weight 6. Disease Soft Tissue cuts and wound and abscesses Caused by the following bacterial infections: S aureus, streptococcus agalactiae, viridans streptococci Corynebactereium minutissimun, Clostridium spp, Bartonella henselea Formulation Base composition 1.0% Base Carrier Soy Oil PH Gr 99.0% Delivery System Spray-Gel-Cream Delivery Load As required 7. Disease Parasitic disease caused by endoparasities or ectoparasites such as Helminthiasas, Trichostrongylus, Ostertagia, Nematrodris, Cooperia, Ascaris, Bunostomum. Formulation Base composition 1.0% Base Carrier water 98.9% Vitamin E 0.1% Delivery System Capsule 1 gram Delivery Load 1 Capsule per 10 kilo body weight 8. Disease Infections by ectoparasitic arthropods such as ticks, mites, lice, stable flies, hornflies, blowflies, fleas. Formulation Base composition 2.0% Base Carrier Soy Oil 98.0% Delivery System Spray-Gels-Creams 9. Disease Avian Influenza Formulation Base composition 0.02% Water 99.96% Vitamin 0.002% Delivery System Drinking water Prevention System Delivery Load As required: Chick will drink twice what they eat a day -
TABLE 3 % v/v Species MIC MCC Aeromonas hydrophila ATCC7966 0.01 0.01 Bacillus cereus ATCC11778 0.03 0.06 Clostridium perfringens ATCC12915 0.03 0.01 Enterococcus faecalis NCTC8213 0.125 0.25 Escherichia coli ATCC 25922 0.06 0.06 Escherichia coli ATCC105365 0.03 0.03 Enterbacter aerogenes ATCC13048 0.06 0.125 Klebsiella pneumoniae ATCC13883 0.03 0.03 Listeria monocytogenes ATCC35152 0.03 0.06 Listeria monocytogenes 001/05 0.06 0.125 Listeria monocytogenes 002/05 0.06 0.125 Listeria monocytogenes 007/05 0.06 0.06 Listeria monocytogenes 010/05 0.06 0.06 Listeria monocytogenes 011/05 0.03 0.125 Listeria monocytogenes 013/05 0.03 0.125 Listeria monocytogenes 323/01 0.03 0.125 Listeria monocytogenes 327/04 0.06 0.125 Listeria monocytogenes 328/04 0.06 0.25 Listeria monocytogenes NCTC 7923 0.06 0.125 Proteus vulgoris NCTC4635 0.03 0.03 Serratia odorifera ATCC33077 0.06 0.125 Shigella flexneri ATCC12022 0.03 0.03 Shigella sonnei ATCC25931 0.03 0.03 Staphylococcus. aureus ATCC9144 0.03 0.06 Staphylococcus aureus ATCC33592 0.03 0.06 Streptococcus agalactiae ATCC13813 0.005 0.005 Streptococcus bovis ATCC9809 0.06 0.125 Vibrio cholera M3695 0.01 0.01 Vibrio parahaemolyticus ATCC43996 0.01 0.01 Vibrio vulnificus ATCC29306 0.01 0.01 Yersinia enterocolitica ATCC27729 0.03 0.06 Campylobacter jejuni NCTC11351 0.06 Campylobacter jejuni 361/04 0.06 Campylobacter jejuni 362/04 0.06 Campylobacter jejuni 384/04 0.06 Campylobacter jejuni 387/04 0.06 Campylobacter jejuni 38/05 0.06 Campylobacter jejuni 27/05 0.06 Campylobacter jejuni 405/04 0.06 Campylobacter jejuni 412/04 0.06 Campylobacter jejuni 413/04 0.06 Campylobacter jejuni 416/04 0.06 Salmonella Salford WACC1 0.125 0.125 Salmonella Typhimurium 0532 0.06 0.06 Salmonella Typhimurium 018331 0.06 0.06 Salmonella Infantis 017431 0.06 0.125 Salmonella Singapore 0402 0.06 0.06 Salmonella Livingstone 017424 0.06 0.06 Salmonella Livingstone 011626 0.06 0.125 Salmonella Livingstone 011655 0.06 0.125 Salmonella Liverpool 10674 0.06 0.06 Salmonella Cerro 012823 0.06 0.125 Salmonella species ATCC12915 0.06 0.06
Claims (8)
1. A method for the treatment or prophylaxis of a microbial, fungal, or mold infection in an animal, comprising the step of administering to said animal or locus thereof in an amount effective to prevent, reduce, or eliminate the infection, a composition derived from the essential oil of a Myrtaceae plant wherein at least about 85% of the monoterpene content of the oil has been removed.
2. A method for the treatment or prophylaxis of a pest infestation in an animal, the method comprising administering to said animal or the locus thereof in an amount effective to prevent, reduce, or eliminate the infestation, a composition derived from the essential oil of a Myrtaceae plant wherein at least about 85% of the monoterpene content of the oil has been removed.
3. The method of claim 1 or claim 2 , wherein the Myrtaceae plant is Melateuca alternifolia.
4. The method of claim 1 or claim 2 , wherein the monoterpenes have been removed under reduced pressure at a temperature of less than 50° C.
5. The method of claim 1 or claim 2 in which the composition comprises between about 40 to about 60% terpen-4-ol and between about 8 to about 30% sesquiterpenes.
6. The method of claim 1 , wherein the microbe is a bacterium and the animal is a ruminant.
7. A method for the treatment or prophylaxis of paratuberculosis in a ruminant, the method comprising administering to the ruminant, an effective amount of a composition derived from the essential oil of a Myrtaceae plant, wherein at least about 85% of the monoterpene content of the oil has been removed.
8. A method for the treatment of prophylaxis of a mite infestation in a honeybee colony, the method comprising administering to the locus of the colony a vaporised composition derived from the essential oil of a Myrtaceae plant, wherein at least about 85% of the monoterpene content of the oil has been removed.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/779,146 US20080026083A1 (en) | 2006-07-17 | 2007-07-17 | Antimicrobial and pesticidal compositions and methods comprising reduced monoterpene oil extracted from myrtaceae |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83141306P | 2006-07-17 | 2006-07-17 | |
US11/779,146 US20080026083A1 (en) | 2006-07-17 | 2007-07-17 | Antimicrobial and pesticidal compositions and methods comprising reduced monoterpene oil extracted from myrtaceae |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080026083A1 true US20080026083A1 (en) | 2008-01-31 |
Family
ID=38957173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/779,146 Abandoned US20080026083A1 (en) | 2006-07-17 | 2007-07-17 | Antimicrobial and pesticidal compositions and methods comprising reduced monoterpene oil extracted from myrtaceae |
Country Status (2)
Country | Link |
---|---|
US (1) | US20080026083A1 (en) |
WO (1) | WO2008010188A2 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011068415A3 (en) * | 2009-12-02 | 2011-07-28 | Ewos Innovation As | Methods and feed compositions for masking of fish semiochemicals |
JP2011523850A (en) * | 2008-05-28 | 2011-08-25 | マース インコーポレーテッド | Food |
US20120046367A1 (en) * | 2010-08-23 | 2012-02-23 | Yih Kuang-Hway | Essential oil composition with anti-free radical ability |
CN102746946A (en) * | 2012-07-27 | 2012-10-24 | 上海春风园艺有限公司 | Method for extracting geraldton wax essential oil |
WO2013051953A2 (en) * | 2011-10-06 | 2013-04-11 | Instytut Przemysłu Organicznego | Use of essential oils to manufacture mite controlling product in honey bees |
US20130331462A1 (en) * | 2009-06-12 | 2013-12-12 | Bayer Cropscience Lp | Methods of inhibiting, preventing, killing and/or repelling insects using simulated blends of chenopodium |
CN104083615A (en) * | 2014-06-29 | 2014-10-08 | 虞志秋 | Traditional Chinese medicament for treating puerperal fever of cattle |
AU2011244887B2 (en) * | 2011-02-01 | 2015-07-23 | Stephen Daniel Matthews | The Manufacture of a Low Molecular Weight Hydrocarbon Fluid |
US20160089477A1 (en) * | 2014-09-25 | 2016-03-31 | Acell, Inc. | Porous foams derived from extracellular matrix, porous foam ecm medical devices, and methods of use and making thereof |
US9572850B2 (en) | 2009-08-07 | 2017-02-21 | Mars, Incorporated | Use of cajeput and Pimenta racemosa extract for treating parasitic infestation of fish |
US20170347767A1 (en) * | 2016-06-03 | 2017-12-07 | Lisa Hudson | Lice preventive headband |
EP3675887A4 (en) * | 2017-08-28 | 2021-04-07 | C&J Lab Pty Ltd. | Monoterpene compositions and uses thereof |
US11390924B2 (en) | 2013-06-14 | 2022-07-19 | Mars, Incorporated | Assay and method |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0623618D0 (en) * | 2006-11-27 | 2007-01-03 | Mars Uk Ltd | Composition |
GB0623619D0 (en) * | 2006-11-27 | 2007-01-03 | Mars Uk Ltd | Composition |
GB0625429D0 (en) * | 2006-12-20 | 2007-01-31 | Mars Uk Ltd | Composition |
WO2009044241A1 (en) * | 2007-09-03 | 2009-04-09 | Max Reynolds | The method of treatment or prophylaxis of an arbovirus infection using oil composition derived from a melaleuca plant |
GB0809046D0 (en) * | 2008-05-19 | 2008-06-25 | Reynolds Max | Cancer treatment |
CN104306571A (en) * | 2014-11-04 | 2015-01-28 | 新疆生产建设兵团第二师畜牧兽医工作站 | Traditional Chinese medicine composition preparation for preventing and treating mastitis of dairy cows and dairy goats |
CN107837347A (en) * | 2017-12-08 | 2018-03-27 | 叶盛清 | A kind of Chinese medicine composition for treating urinary tract infections and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5472684A (en) * | 1993-06-02 | 1995-12-05 | Colgate Palmolive Company | Oral compositions for plaque and gingivitis |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001278718A (en) * | 2000-03-28 | 2001-10-10 | Nissan Chem Ind Ltd | Seaweed-proofing agent |
-
2007
- 2007-07-17 WO PCT/IB2007/052853 patent/WO2008010188A2/en active Application Filing
- 2007-07-17 US US11/779,146 patent/US20080026083A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5472684A (en) * | 1993-06-02 | 1995-12-05 | Colgate Palmolive Company | Oral compositions for plaque and gingivitis |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011523850A (en) * | 2008-05-28 | 2011-08-25 | マース インコーポレーテッド | Food |
US9295250B2 (en) * | 2009-06-12 | 2016-03-29 | Bayer Cropscience Lp | Methods of inhibiting, preventing, killing and/or repelling insects using simulated blends of chenopodium |
US20130331462A1 (en) * | 2009-06-12 | 2013-12-12 | Bayer Cropscience Lp | Methods of inhibiting, preventing, killing and/or repelling insects using simulated blends of chenopodium |
US9572850B2 (en) | 2009-08-07 | 2017-02-21 | Mars, Incorporated | Use of cajeput and Pimenta racemosa extract for treating parasitic infestation of fish |
WO2011068415A3 (en) * | 2009-12-02 | 2011-07-28 | Ewos Innovation As | Methods and feed compositions for masking of fish semiochemicals |
US20120046367A1 (en) * | 2010-08-23 | 2012-02-23 | Yih Kuang-Hway | Essential oil composition with anti-free radical ability |
AU2011244887B2 (en) * | 2011-02-01 | 2015-07-23 | Stephen Daniel Matthews | The Manufacture of a Low Molecular Weight Hydrocarbon Fluid |
WO2013051953A3 (en) * | 2011-10-06 | 2013-09-26 | Instytut Przemysłu Organicznego | Use of essential oils to manufacture mite controlling product in honey bees |
WO2013051953A2 (en) * | 2011-10-06 | 2013-04-11 | Instytut Przemysłu Organicznego | Use of essential oils to manufacture mite controlling product in honey bees |
CN102746946A (en) * | 2012-07-27 | 2012-10-24 | 上海春风园艺有限公司 | Method for extracting geraldton wax essential oil |
US11390924B2 (en) | 2013-06-14 | 2022-07-19 | Mars, Incorporated | Assay and method |
CN104083615A (en) * | 2014-06-29 | 2014-10-08 | 虞志秋 | Traditional Chinese medicament for treating puerperal fever of cattle |
US20160089477A1 (en) * | 2014-09-25 | 2016-03-31 | Acell, Inc. | Porous foams derived from extracellular matrix, porous foam ecm medical devices, and methods of use and making thereof |
US20170347767A1 (en) * | 2016-06-03 | 2017-12-07 | Lisa Hudson | Lice preventive headband |
EP3675887A4 (en) * | 2017-08-28 | 2021-04-07 | C&J Lab Pty Ltd. | Monoterpene compositions and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2008010188A3 (en) | 2009-04-30 |
WO2008010188A2 (en) | 2008-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080026083A1 (en) | Antimicrobial and pesticidal compositions and methods comprising reduced monoterpene oil extracted from myrtaceae | |
Thomas et al. | Pathogenecity of Pseudomonas aeruginosa in Oreochromis mossambicus and treatment using lime oil nanoemulsion | |
Bader et al. | Use of praziquantel to control platyhelminth parasites of fish | |
Filippich et al. | Hepatotoxic and nephrotoxic principles in Terminalia oblongata | |
Higgins | Observations on the diseases of the arabian camel (Camelus dromedarius) and their control. A review. | |
WO2004091307A2 (en) | Feed additives against diseasse infection in terrestrial and aquatic animals | |
US20120065273A1 (en) | Tto-based wide spectrum therapeutics, disinfectants & anesthetics for use in aquaculture | |
CN111000801B (en) | Plant essential oil spray emulsion capable of being applied to lung | |
Deem | Fungal diseases of birds of prey | |
KR20130071028A (en) | Agent for sacbrood virus of bees | |
JP2005230007A (en) | Feed effective for invermination of fishes, additive for feed, fat and oil and medicated bath agent | |
WO2011101367A1 (en) | Product for removing sea lice | |
Hassan et al. | Prevalence of yeast infections in small in ruminants with particular references to their treatment by some natural herbal extracts | |
KR100782500B1 (en) | Antifungal agent comprising natural plant extracts | |
Boyko et al. | The impact of certain flavourings and preservatives on the survivability of eggs of Ascaris suum and Trichuris suis | |
Brasil et al. | In vitro and in vivo antiparasitic action of essential oils of Lippia spp. in koi carp (Cyprinus carpio) fed supplemented diets. | |
CN109833296A (en) | Can the new merit chigger disease of prevention and control plants essential oil microemulsion formulation and preparation method thereof | |
Paliy et al. | Efficacy of flea and tick collars against the ectoparasites of domestic animals | |
CN107115549B (en) | A kind of application of livestock and poultry cultivation air modifying agent in the drug for preventing and treating porcine respiratory disease is prepared | |
Salisch | Recent developments in the chemotherapy of parasitic infections of poultry | |
Ordóñez et al. | Antibacterial activity of plant extracts against Streptococcus equi subsp. zooepidemicus isolates from guinea pigs with lymphadenitis in Ecuador | |
Rizzo et al. | Lethal and sublethal effects of carlina oxide on Tetranychus urticae (Acari: Tetranychidae) and Neoseiulus californicus (Acari: Phytoseiidae) | |
JP6508754B2 (en) | Infectious disease preventive agent of salmon fry for release | |
WO2017091915A1 (en) | Composition, method and use for controlling fungal infection caused by nosema ceranae fungus in apis mellifera bee colonies, comprising application, as a syrup (pj-cd14) and aerosol (pa-cd14), of an effective quantity of an essential oil (cd14) obtained from cryptocaria alba (peumo) leaves | |
KR102169044B1 (en) | Animal drink comprising bee venom for prevention or improving avian influenza |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |